key figures millions chf figures reported figures reported financial statements adjusted basisa change change sales ebitdab operating profit net income research development additions property plant equipment personnel number employees december ratios ebitda sales operating profit sales net income sales research development sales data shares nonvoting equity securities chf earnings per share nonvoting equity security diluted dividend per share nonvoting equity securityc adjusted figures presented improve comparability current future consolidated results show recurring accounting effects new revised international accounting standards became effective january acquisition remaining outstanding shares genentech june already taken place beginning furthermore exclude special items impairment charge gain sales genentech labcorp shares vitamin case genentech legal settlements credit changes accounting policy include continuing businesses ie excluding fragrances flavours b ebitda earnings interest financial income tax depreciation amortisation including impair ment corresponds operating profit excluding depreciation amortisation impairment c dividend proposed board directors figure include special dividend relating spinoff fragrances flavours divisionletter chairman letter ceo board directors executive committee group performance glance divisions pharmaceuticals diagnostics vitamins fine chemicals roche group human resources annual report group accounts safety environmental protection roche holding ltd basel annual accounts table contents finance financial review consolidated financial statements notes consolidated financial statements report group auditors multiyear overview consolidated income statement adjusted basis holding finance companies roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors roche global market presence operating subsidiaries associated companies table contents letter chairman groups overall results good net income operating profit ebitda sales reached record highs however figures last year also show lower expected growth pharmaceu ticals divisions prescription medicines diagnostics division contrast held topped previous high market share core businesses similarly vitamins fine chemicals division reinforced global market leadership position continuing face fierce competition letter chairmannet income increased year organisational measures deal reaching remarkable total bil itparticularly key us mar lion swiss francsa increase ketwe expect sales growth inoperating profit strong pharmaceuticals division improve financial result major contribu second half tors impressive performance gains special itemsparticularly saw number positive successful sale genentech shares developmentstoday note also major impact groups satisfactionfor examplethat financial statements net income operating profit gross cash flow sales adjusted basisconsolidated sales advanced previous reached record highs year billion swiss francs expressed local currenciessales merger boehringer mannheim grew diagnostics division far exceeded expectations annual general meeting proven strategically important board directors propose move entire groupthe phar dividend increase maceuticals division also recorded swiss francs per share non advances several market segments voting equity securityif approved including consumer healthcareour thiswill fourteenth consecutive research development portfolio dividend increase forms solid basis futurethe positive sales growth posted genen challenging year throughout history group guided employeesthanks profession alism forwardlookingproactive commitment innovation innovation focusthey played pivotal role record performancei want express remain key success future sincere appreciation fortheir personal contribution tech mentioned well groups overall success majority interest leading us biotechnology company con long string successes tinue major strategic impor impressive standardssales tance future prescription medicines area special concern vitamins fine chemicals divi noted earlierprescription drug sales sion continued meet challenges weaker expectedlagging intensely competitive market behind average market growth rate placesales volumes increased negative impact price yearand division achieved addi roche securitieswe taking tional cost savings intro development seriously duction improved production implemented necessary strategic technologies processes letter chairman lastlyon june spun fragrances flavours division independent group operating givaudan namegivaudans shares distributed special dividend holders roche shares non thank fritz gerber voting equity securities fritz gerber retiring chairman board directors roche holding ltd past two decades annual general meeting april would therefore like pay tribute made major progress towards goal man many years roche made major contribution ranking among industry leaders group businessesbut guarantee future successwe fritz gerber became chairman board directors chief executive officer afford stand stillfor left much thank twenty years instrumental behind dowe necessary building roche global leader farsighted timely actions many resources must make occasions helped roche achieve extraordinary success prepared well themthis involve questioning challenges future time ability welcome change oppor established ways things tunity openness new ideas proven decisive strengths fritz gerber courage strike new realised well many others essential group focus core directionsthese challenges requir competencies took steps necessary achieve focus skill ing great deal personal initiative breadth vision great believer people always keenly interested flexibility everyones part staff development unwavering commitment innovation shown throughout chairmanship set example entire group one first recognise throughout history group great potential biotechnology secured roche majority holding hasbeen guided commitment us company genentech innovationand firmly convinced innovation remain key board directors executive committee employees roche would like toour success futurewe express deep appreciation fritz gerber recognition outstanding service devote full energies continuing board directors decided appoint honorary chairman roche pathin years ahead aim also remain member board directors roche holding ltd delighted achieve dynamic organic growth mr gerber retaining close ties company fuelled innovative product port folioandas pastwe remain open opportunities andres f leuenberger franz b humer strengthen position vicechairman board directors delegate board directors acquisitions diverse network alliances letter chairmanworking togetherfranz bhumer board directors elected succeed chairman theexecutive committee employees build groups future entrepreneurial courage vision energy fritz gerber letter chairman letter ceo roche look back profitable net income rose billion swiss francs robust gain previous year adjusted sales increased billion swiss francs operating profit including gains sale genentech stock billion swiss francs gross cash flow ebitda divisions showed even stronger growth advancing billion swiss francs financial income significant contributor group profitability increased strong billion swiss francs letter ceoour impressive earnings growth showed gain billion positive impact groups swiss francsgrew roughly financial positionthe ratio equity rate sales minority interests assets increased years end hold expect pharmaceuticals sales ings cash marketable securities accelerate second half totalled nearly billion swiss francs portfolio includes innovative reporting net debt bil products major therapeutic areas lion swiss francs end wehave become net creditor impressive earnings growth positive impact net liquidity position billion swiss francswe use strong cash flow groups financial condition three years investments growing boehringer mannheim acquisition high net businesses strategically reinforce roches presence leading health liquidity position solid balance sheet care company net income also increased year oncologyvirology trans adjusted basisrising plantation medicinelast year also billion swiss francs facilitate com acquired global rights kytrila parisonsthese figures exclude special medicine used oncologyin connec items include continuing tion movewe sold north operationsanother good per american marketing rights coreg formance diagnostics division cardiovascularwe taking recorded doubledigit gains stepbystep approach developing insales operating profitand market xenical exceptionally strong financial result major growth driversadjusted received six approvals financial income increased european unionfour billion swiss francs united states three japan new products indicationsaddi sales pharmaceuticals tionallywe filed ten regulatory division rose swiss franc terms applications key marketsincluding billionthey application pegasys hepati inlocal currenciesthis slowdown tiscother new drugssuch iban growth resulted loss market dronate osteoporosis hiv sharesales affected expiry fusion inhibitor tare advanced ofpatent coverage verseddormicum stage developmentin terms anesthesia ticlid stroke quantity qualityour clinical united statesother factors included pipeline looks promisingwith seasonally weak sales rocephin bac total projects different terial infections flattening sales molecules developmentaddition xenical obesity following extremely allywe improved position successful launches major markets forfuture growth pursuing active adjusted operating profitwhich licensing policyin february letter ceo forexamplewe acquired innovative achieving costeffective treatment mentdevelopment work novel anticancer medicine latestage devel comes address causes dis taqman analyser also well advanced opment osi pharmaceuticals easeall four roche diagnostics units first new generation labora produced pioneering research new tory systems designed make routine also anticipate sustained growth nextgeneration products pcrbased testing significantly faster consumer health businessafter make us even stronger competitor easiertaqman automates every declining sales otc expect doubledigit sales growth step testing processfrom sample products rebounded last yeargrowing continue preparation detectionwe also continue steadily expanding range pcrbased test kits another good performance diagnostics division recorded doubledigit gains sales operating profit roche molecular biochemicalsthe fourth diagnostics businesses major growth driver focus increasingly supplying innovative system technologies use local currencies accuchek blood glucose meter pioneering fields genomics billion swiss francsa tight focus marketed roche patient care proteomicsnow areas intense eight global brands one factor already roches topselling product research activitythe latest example contributing turnaround annual sales totalling rts worlds first commercially billion swiss francsfollowing available system automated cellfree diagnostics division posted successful integration ofavl medical protein synthesislaunched another good result instrumentswe also rts play major role background sluggish overall market leaderin fastgrowing pointofcare fastgrowing proteomics market growthwith sales advancing segment hospital diagnostics billion swiss francsexpressed vitamins fine chemicals local currenciesthis equivalent despite fierce market competitionwe division recorded volume increases increase resultwe anticipate positive future roche major product segmentsgaining gained additional market share laboratory systemsas continues market share background strengthened global leadership benefit launch additional intense competitionhoweverprice positiondivisional operating profit userfriendly analysers new test erosion sale medicinal million swiss francs reagents pursues efforts cut feed additives business early may rose even sharplyboosting costs raise productivity caused sales revenue decline divisions profit margin one per local currencies bil centage point roche molecular diagnostics lion swiss francsas resultoperating amarket share profit million uncompromising focus cus undisputed leader continued swiss francsdespite improved produc tomer needs aboveaverage sales record dynamic growthour tests tivitywith new products coming gains divisions business considered gold standard diag marketleadingedge competencies units contributed record result nosing infectious diseasesduring research production prospects current year year signed licensing agreement expanding global presenceparticularly excellentat every stage health chiron corporation relating emerging markets ofasia care delivery identifying disease tests hepatitis cthe agreement latin americawe ideally equipped predispositions monitoring treat marks end protracted liti maintain leadership com ment responses diagnostic tools gationhas opened way inten petitive global marketwe expect see increasingly important factor sive development attractive seg positive sales growth letter ceoadditional lawsuits relating roche employees around globe pricefixing agreements revealed remain key success factor vitamins industry futurei would like take addi settled indirect customers tional opportunity thank united statesthe formal investigation hard work valuable opened mid european contributions made build union still progressadequate ing strengthening company provisions made togetherwe tackle challenges expenditures expected arise ahead keep roche track thevitamin case success positioned well meet challenges aheadour strengths include great financial flexi bilitya solid balance sheetthe pharmaceuticals divisions strong pres ence hospital specialist seg mentsour strategic collaboration franz bhumer genentecha rich research devel opment pipelinethe turnaround roche consumer health global leadership diagnostics vitaminsas global pharmaceutical company world market leader diagnosticswe convinced ideally equipped benefit revolution taking place genetics genomics proteomicswith use strong cash flow investments growing businesses strategically reinforce roches presence leading healthcare company broad implications medical science fields interests diagnostics pharmaceuticals con verge groundbreaking integrated healthcare solutions drugs tailored needs specific patient populations born finallythe tremendous professional ism dedication nearly letter ceo board directors executive committee board directors general meeting elected peter brabeck board directors elected letmatheceo nestlto join franz bhumer new chairman board subject reelection board annual general meeting former cantonal councillor kurt april dr humer assume jenny step board chairmanship april directors annual general continuing serve chief meetingand charles weissmann executive officer available another termin many years board recognition major contribu men contributed greatly build tions rochethe board directors ing strengthening groups named longstanding chairman businessesand extend fritz gerber honorary chairman sincere thanksthe board directors boardhe continue serve proposes businessman national board councillor walter frey john bell nuffield professor ofclinical werner stauffacher retired medicine oxford universitybe board directors annual elected new members ofthe board general meetingfollowing appoint ment president ofthe swiss academy board committees medical scienceswe wish thank within scope responsibilities profstauffacher valuable con board directors roche tributions group ten holding ltd delegated certain tasks years boardthe annual fuller attention chairman board directors executive committeeand vicechairmen boardthe accounting systems procedures executive committee audit committeethe finance organisation scope finan end henri bmeier investment committee com cial controlling retired roches chief financial offi pensation committee financial planningbudgets bud cera position held yearsthe get execution board directors wishes express chairman vicechairmen financial reporting shareholders deep appreciation dr meierwhose chairman two vicechairmen general public outstanding achievements board directors serve jointly financial investments decisive factor groups success nomination committeein continue serve member capacity prepare proposals committee approves capital expen boardanton affentranger board regarding appointment ditures divestments valued named new chief financial new members concerned million swiss francs officer succession planning evaluation candidates executive com confident new teams board mittee directors executive committee ideally equipped audit committee audit committee composed keep group track success exclusively board members fritz gerber chairman board directors members executive com mittee compensation committee william mburns became head committee assists board compensation committee pharmaceuticals division january overseeing management groups composed three board members franz bhumerwho headed businessesparticularly respect members executive division end financial legal matters com committeeupon application concentrate overall group manage pliance internal business chairmanthe committee approves ment administrative policiesincluding poli groups compensation policy cies safety environmental pro compensation received members richard laubehead pharma tectionin particularthe committee executive committeegeneral ceuticals divisions global consumer reviews scope extent exter managers major roche affiliates health businesshas appointed nal internal auditsthe indepen highlevel employeesin addi executive committeeeffective dence objectivity auditors tionit approves employee option pro january establishment appropriate grammes equity profit organisational structures safety sharing devices defines general environmental protection policy company pension benefits postemployment benefit finance investment committee plans finance investment committee assists board directors issues relating financeinvestment capital assets evaluating risks areasspecificallythe committee reviews board directors executive committee board directors january left andres f leuenberger kurt jenny rolf hnggi andr hoffmann fritz gerber henri b meier franz b humer peter brabeckletmathe charles weissmann andreas oeri name year birth term ends board directors dr hc fritz gerber chairman dr andres f leuenberger cid vicechairman rolf hnggi cid cid vicechairman dr franz b humer delegate peter brabeckletmathe cid andr hoffmann cid cid prof kurt jenny cid dr henri b meier dr andreas oeri cid prof charles weissmann cid secretary dr gottlieb keller board directors franz b humer stand another term board directors fritz gerber retire chairman cid finance investment committee annual general meeting board directors elected dr humer new chairman cid audit committee subject reelection board annual general meeting fritz gerber remain member cid compensation committee board retiring chairman kurt jenny retire board directors charles weissmann decline another term january board annual general meeting board propose annual general meeting elect walter frey john bell board directors executive committeeexecutive committee january left william burns jonathan knowles markus altwegg franz b humer richard laube heino von prondzynski daniel villiger anton affentranger name year birth position executive committee dr franz b humer chief executive officer anton affentranger chief financial officer william burns pharmaceuticals division heino von prondzynski diagnostics division dr markus altwegg vitamins fine chemicals division richard laube pharma consumer health prof jonathan knowles global pharmaceutical research dr daniel villiger corporate services secretary pierre jaccoud executive committee statutory auditors ernst young ltd roche holding ltd group auditors pricewaterhousecoopers ag january board directors executive committee group performance glance price development nonvoting equity security genussscheinin chf roche nonvoting equity security adjusted swiss market index rebased helped partly special gainsroche roches sales averaged double projects expanding market increased profitability enor digit growth past five years ing distribution operations mously recent yearswhile continu rising period billion ing strengthen consolidated swiss francsnet income gross saw anotherimpressive balance sheetsto facilitate compar cash flow ebitda climbed improvement balance sheet isons mediumterm performance steadilyand exceeded billion positionjust three years changesthe figures presented billion swiss francsrespectively boehringer mannheim acquisition exclude special items first timein order remain roche net creditorwith refer solely ongoing operations astrong innovator one net liquidity position billion spunoff fragrances flavours worlds leading healthcare groups swiss francsthe ratio equity business therefore excluded major marketswe consistently minority interests total assets rose used high cash inflows invest three percentage points ments research development avery solid group performance glancesales divisionin millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others group figures net income millions chf net income per share ebitda millions chf nonvoting equity security chf operating profit millions chf research development millions chf additions property plant equipment millions chf special charges figures adjusted basis figures fully comparable previous years due givaudan spinoff genentech transactions accounting policy changes group performance glance latot latot latot latot latot roche develops diagnostic tests promote effective individualised care cancer patients tests make possible predict probability clinical benefit particular treatment monitor patients responses medicines like xeloda herceptin elsa k treated colorectal cancer xeloda anticancer drug inactive reaches tumour tissues drugs good tolerability profile improved elsas quality life take xeloda tablet form home also time spend grandchildrenpharmaceuticals division brief millions chf change sales rx genentech otc ebitda operating profit rd expenditures employees adjusted basis pharmaceuticals pharmaceuticals business accounts almost twothirds group sales posted increases sales revenue operating profit although sales prescription medicines grow fast market average achieved significant milestones number major therapeutic areas particularly oncology transplantation virology sales us biotechnology company genentech hold majority interest close collaborative relationship continued outperform us market non prescription medicines sector roche consumer health recorded substantial rise sales showing back growth track roche submitted ten marketing applications new chemical entities supplemental indications late year also acquired global rights kytril drug used chemotherapy pharmaceuticals operating profit reached million swiss francswith operating margin ofthe divisions ebitda totalled million swiss francsor sales focusing pharmaceuticals business therapeutic areas significant unmet medical needs special expertise experiencein achieved fur ther significant advances several areas oncology leadership built inno vation continued reinforce strong presence oncologyamong many factors contributing average growth potential market major advances early diagnosisbetter targeted therapy based identification cancer sub types rapid acceptance innova tive new products sales xelodaa novel tumourselec confident ability launch one tive cancer drug oral usegrew bymore million two major new products additional indications swissfrancsxeloda monotherapy every year ensuring continued growth approved countries metastatic breast cancer resistant pharmaceuticals division coming years certain standard chemotherapiesthis franz b humer ceo head pharmaceuticals division december product filed breast cancer treatment japan study results published late year prescription medicines global showed xeloda docetaxel presence key therapeutic areas first chemotherapy combination reinforced sales pharmaceuticals produce superior survival metastatic division rose local curren breast cancer patients compared cies million swiss francs withmonotherapyxeloda also prescription drug sales including approved firstline treatment genentech increased million metastatic colorectal cancer europe swiss francsfor yearonyear growth us food drug administration rate swiss francs fda issued letter approva local currencieson adjusted basis bility drug indication pharmaceuticalsa total eight medicines sales half billion swiss francs among divisions top ten products roaccutan mabthera cellcept neo jointly marketed roche genentech recormon herceptin viracept posted dou includes supplemental indications updated mid bledigit sales growth local currencies xenical february consolidated position leading pharmaceu jointly developed roche gilead sciences tical weight loss weight management topselling prescription products including genentech product generic name indication sales millions chf rocephin ceftriaxone bacterial infections roaccutanaccutane isotretinoin severe recalcitrant nodular acne xenical orlistat weight loss weight management mabtherarituxan rituximab lowgrade nonhodgkins lymphoma cellcept mycophenolate mofetil transplantation prevention acute rejection neorecormon epoetin beta anemia herceptin trastuzumab metastatic breast cancer viracept nelfinavir mesylate hiv infection dormicumversed midazolam anesthesia sedation nutropinprotropin somatropinsomatrem growth hormone furtulon doxifluridine cancer colon breast stomach activase alteplase myocardial infarction neupogen filgrastim gcsf neutropenia pulmozyme dornase alfa dnase cystic fibrosis lexotan bromazepam anxiety tension states invirasefortovase saquinavir hiv infection rocaltrol calcitriol osteoporosis roferona interferon alfaa hepatitis b c cancer madopar levodopa benserazide parkinsons disease dilatrend carvedilol heart failure hypertension angina pectoris torem torasemide hypertension cymevenecytovene ganciclovir cytomegalovirus infection rivotril clonazepam epilepsy major product approvals launches product generic name indication country cellcept mycophenolate mofetil prevention acute rejection pediatric kidney transplantation usa prevention acute rejection liver transplantation eu switzerland usa herceptin trastuzumab metastatic breast cancer eu roferona ribavirin interferon alfaa chronic hepatitis c eu tamiflu oseltamivir treatment influenza b canada japan latin america prevention influenza b usa treatment influenza b children aged one year older usa xenical orlistat weight loss weight management australia china xeloda capecitabine metastatic colorectal cancer australia canada eu switzerland pharmaceuticals herceptin sales also sharply facilitate development combina advancing tion regimens including herceptin million swiss francsherceptin first breast cancer drug selec mabtherarituxanthe first humanised tively target receptorthus monoclonal antibody approved blocking signal pathways cause cancer treatmentlikewise continued uncontrolled cell growthroche intro show strong growthas sales climbed duced herceptin europe million swiss prescription produtcs including genentech metabolic disorders japan others dermatology others latin america central nervous system oncology sales region sales therapeutic area infectious diseases north america europe cardiovascular diseases virology inflammatory autoimmune diseases francsthis product indicated total sales division millions chf certain forms ofnonhodgkins lymphoma nhla cancer ofthe lymphatic systemroche holds world wide marketing rights mabthera outside united states co market drug japanused monotherapy combination chemotherapymabtherarituxan highly effective well tolerated patientsourobjective register thedrug firstline use lowgrade nhland inautoimmune diseases marketing application also areas inwhich mabtherarituxan submitted year japan potential revolutionise treatment genentech markets breakthrough treatment united stateswhile bondronata thirdgeneration bisphos roche holds exclusive marketing rights phonate bisphosphonate countriesseveral large available intravenous oral scale studies currently evaluating formulations management additional indicationsduring year hypercalcemia malignancyexperi entered research alliances enced strong demandin oral bristolmyers squibb aventis form bondronat submitted pharmaceuticals approval metastatic bone disease medicineafter strong start sales duration severity flu breast cancer patients levelled offand plans decreasing risk complications developed return growthkey activ product available influenza sales neorecormon also rose ities include programmes inform treatment united statesjapan strongly mainly due patients health benefits oflos canadaswitzerland many coun development new market segments ing weighteducate right tries southern hemispherethe oncology dialysisa marketing way use xenical achieve longterm additional data requested filing application use hematological weight control provide support eu regulatory authorities cancers filed european encouragement therapyother submitted february union july initiatives aimed realising applications additional indica drugs largely untapped potential vari tionsin united states tamiflu december roche strength ous patient populations example wasapproved influenza prevention ened oncology portfolio acquir overweight men address weight adults adolescents aged years ing global rights antinausea related risk factors patients type older treatment drug kytril smithkline beecham diabetesdyslipidemia hyperten influenza children aged one year kytril given cancer patients sionrecent studies shown xenical older suppress severe debilitating lead significant weight loss nausea vomiting associated improved weight control patients chemotherapy type diabetesallowing patients reduce dose ofglucoselowering early roche genentech medicationroche launched clinical signed agreement osi phar development programme aimed maceuticals new york co extending use xenical development commercialisation conditionsresearch continues charac novel anticancer drugthe drug terise secondgeneration lipase inhibi known osiis currently torandotherapproachestowardsobesity phase ii clinical trials lunghead neck ovarian cancer research development marketing teams work even closely making expanding number position weight managementxenical estab sure medicines optimally serve doctors lished itselfas worlds leading pre patients needs able fully scription pharmaceutical weight loss weight managementit realise products potential future commercially available weight loss product acts locally gastro william burns head pharmaceuticals division since january intestinal tractwhere reduces absorp tion ofdietary fat virology major growth opportuni roches nextgeneration interferon product rolled year ties virology segmentroche pegasyswas submitted review inaustralia indonesia also scored major success tamiflu fda united states received marketing authorisation oral neuraminidase inhibitor treatment hepatitis eu appli chinakorea taiwannow first full year us market cation filed february xenical successfully launched became leading influenza medicine twolargescale clinical trials compar inmajor countrieswe want steadily tamiflu prevents influenza virus ing pegasys standard interferon develop market novel replicatingthus reducing therapy shown pegasys provide pharmaceuticals statistically superior efficacy inhepati schedule ofviracept also felt tis cpegasys currently theonly advantage patients pegylated interferon shown tobe safe effective hepatitis c patients sales aids medicines invirase also suffer liver cirrhosis fortovase declined result hepatitis c increasingly recognised increasingly competitive market major cause liver disease fortovase continues deliver full liver failuremore million therapeutic potential saquinavir people worldwide infected andused combination ritona lifethreatening virus virhas maintained leadership pretreated patientsvery promising hiv areaviracept sales con new data supporting use forto tinued solid growth trenddata vase dailylowdose ritonavir clinical trials showed presented conference patients receiving viracept remained retroviruses opportunistic infec therapy significantly longer tions february experienced fewer side effects taking another protease united states submitted inhibitorthe twice daily dosing new drug application valcyt treatment cytomegalovirus retinitis patients aids integrated health care solutions gaining momentum integrated health care solutions ihcs programmes offer opportunities progress made develop improvehealthcare delivery combining innovative diagnostic tests treatments ing entirely new class antihiv forpatients opens way individualised care goal develop medicines known fusion inhibitors products services improve treatment outcomes medicines prevent hiv penetrating enabling health professionals make timely diagnoses predict probability infecting host cellsthe fusion clinicalbenefitand monitor treatment response inhibitor entered phase iii clinical trials phase ii testing initial trials novel diagnostic test early detection heart failure look start promising test runs elecsys analyser launched second half timely diagnosis heart problems improves chances successful transplantation medicine building treatment cardiovascular medicines like dilatrend torem ona position strengthcellcepta potent immunosuppressant used pre oncology scored major technology breakthrough first assay capable vent kidneyheart liver transplant ofanalysing paraffinembedded tissues using sensitive polymerase chain reaction rejectioncontinued show strong pcr method tissue samples used diagnose cancer normally preserved growththe product approved paraffin near future may lead new tests cancers overexpress use liver transplantation protein anticancer medicine herceptin currently offers highly targeted united statesthe european union therapy herpositive breast cancer new possibilities also opening switzerlandin december cellcept measuring enzyme levels tumours important parameter effective use also received us regulatory clearance anticancer medicine xeloda clinical trials currently way validate specific foruse pediatric kidney transplant biomarkers designed facilitate patient selection thus substantially increase recipientsadditional data con response rate drug expect allow xeloda therapy targeted firmed lowtoxicity immuno evenmore effectively patients breast colorectal cancer suppressive regimens combining pharmaceuticalscellcept zenapax significantly expectedsales dormicum improve patientsquality oflifeour verseda drug used hospitals commitment transplantation medicine anesthesia sedationfell nearly also includes major funding million swiss francs roche organ transplantation research dueto patent expiry united foundationan organisation pro states mid motes clinical transplantation research sales carvedilol dilatrendkredex wellestablished products anes coregused treat hypertension thesia infections severe acne angina pectoris chronic heart cardiovascular disease roaccutan failurerose markedly spurred accutane posted doubledigit sales new data major international growthhelped particularly clinical study showing significant positive sales trend north america survival benefit patients severe oral retinoid vitamin derivative chronic heart failureexclusive rights highly effective treatment severe coreg north america sold nodular acnemarketing applications smithkline beecham december new formulation filed dur smithkline beecham roche pre ing year united states viously copromoted product canadain additionwe instituted united stateswe remain supplier various measures defend product effectivesafe welltolerated possible entry generic medicine countries competitors us market second half range roche consumer health focusing services provide prescribers strong brands sales roche patients optimise treatment consumer healthour otc medicines roaccutanaccutane recently businessrose million expanded furtherin united weve returned growth otc sector statesfor examplethe comprehensive pregnancy prevention programme concentrating efforts building core forpatients taking drug strengthened effort prevent global brands fetal exposure potent retinoid richard laube head roche consumer health antibiotic rocephin remained topselling medicinewith sales focus eight otc brands millions chf totalling billion swiss francs product uses sales outpatient parenteral antibiotic aleve analgesic therapy rocephin continued supradyn multivitamin increaseuse drug outpatient bepanthen skin care settings already well established rennie antacid united statescanadaitalythe redoxon vitamin c united kingdomargentina mex berocca multivitamin icoand also introduced saridon analgesic chinajapan central america elevit pronatal multivitamin pharmaceuticals swiss francsin local currency terms sales growth strongest north clinical oncology meeting may sales significant americawhere aleve sales rose genentech announced encourag turnaround previous years sharplyand europewhere roche ing preliminary findings several decline sales wasdue primarily consumer health ranks second phase ii trials evaluating antivegfa restructuring activities commenced theotc marketin latin america monoclonal antibody starve tighter focus key particularly mexicosales grew tumours blood supplythereby global brands fasterthan market thanks highly inhibiting tumour growthroche focused marketing option codevelop comarket compoundphase iii trials consumer selfmedication currently way assess safety efficacy antivegf colo rectalnonsmall cell lung breast cancer also saw approval skin hair care launch genentechs tnkasethe analgesics gastrointestinal products drug currently investigation others four clinical trials designed evaluate sales therapeutic area cold remedies various heart attack treatment regi mens combining tnkase vitamins agents research productivity enhanced boosting productivity setting new eight core brands account genentech outperforming mar standards recently imple half total consumer health sales ket new cancer therapies mented variety strategies includ sales brands increased years close working relation ing initiatives drug optimisation year swiss francs ship genentech become new lead chemistry creation local currenciesaleve became top increasingly important global research informatics system selling productthanks healthy sales scientific commercial point improve productivity growth existing marketsparticularly viewand continues extremely search safeeffective medicines united statesand rollouts new successfulroche held majority flexibleharmonised procedures marketssales supradynroche interest californiabased established research sites consumer healths second strongest biotechnology company since reduce time resources required brandalso showed doubledigit gain genentech sales united place compounds lifecycle entries new marketsnotably states us dol teamsin number new spainand product relaunch lars billion swiss francs research compounds went theunited kingdom driving growth critical preclinical evaluation process supradyn new formulation genentech focuses research total seven new molecular tailored specifically needs development efforts heart disease entities cleared clinical test consumers successfully cancerthe number number ingeighteen new drug compounds launched number european killer diseases united states expected enter preclinical develop marketsall core otc brands two marketed anticancer prod ment end indica also posted healthy growthlargely ucts seven oncology projects tions ranging obesitydepression aresult improved marketing activ pipelinegenentech well positioned alzheimers disease oncology ities particularly area direct play active part fight osteoporosis hiv toconsumer communications cancerat american society pharmaceuticalsnew business model basilea phar pharmaceuticals businessproteomics maceutica continued lead increased number strategy focusing core disease potential target molecules provide areas spinning drug additional stimulus discov discovery activities new biotech ery new therapeutic compounds startupcalled basilea pharmaceutica one objectives roches pro followed earlier spinouts resulting teomics research diagnostics creation two biotech identify proteins used startupsnovuspharma italy new markers preclinical clinical actelion switzerlandas result tests cancermetabolic disorders roches rd knowhow decades inflammatory disease cardiovas accumulated intellectual property relating antibioticsantifungals dermatology integrated metabolic diseases virology broadly based biotechnology com vascular diseases panyroche retain minority oncology interest basilea pharmaceuticawith research projects genitourinary diseases major therapeutic areas option acquire global develop inflammatory diseases ment marketing rights selected central nervous system compounds genomics genetics proteomics forbetter healthcare solutions pharmaceutical research centres progress deciphering human genome provided scientists basel switzerland metabolic disorders wealth ofinformationbut stilla central nervous system great deal ofwork done identify vascular diseases key genetic variations make kamakura japan oncology people susceptible particular nutley new jersey usa metabolic disorders diseasesat roche striving oncology support effortswhich vascular diseases decided step involvement palo alto california usa central nervous system genetics genomics redirect inflammationbone diseases focus ofresearch basel insti genitourinary diseases tute immunologyestablished penzberg germany oncology years agothe institute trans welwyn garden city uk virology formed centre medical geno roche center medical genomics mics associated basel switzerland basic research geneticsgenomics groups global research organisation next years roches pharmaceuticals diagnostics divisions invest roughly mil lion swiss francs strengthening groups proteomics researchin pharmaceuticals currently projects total different molecules clinical development theseprojects generate stream new products ensuring future growth balanced product pipeline product indication phase bondronat oral ibandronate treatment bone metastases breast cancer patients iii antivegf several types solid tumours combination chemotherapy iii neorecormon epoetin beta anemia hematologic malignancies nda filed herceptin trastuzumab adjuvant therapy breast cancer iii mabtherarituxan rituximab intermediatehighgrade nonhodgkins lymphoma combination chemotherapy iii xeloda capecitabine combination therapy breast cancer iii fusion inhibitor hiv infection iii viracept nelfinavir mesylate new formulation hiv infection iii valcyt oral valganciclovir prevention cytomegalovirus disease solid organ transplantation iii valcyt oral valganciclovir treatment cytomegalovirus disease aids nda filed pegasys pegylated interferon alfaa chronic hepatitis c nda filed pegasys pegylated interferon alfaa combined ribavirin chronic hepatitis c iii pegasys pegylated interferon alfaa hivhepatitis c coinfection iii oral ibandronate prevention treatment postmenopausal osteoporosis iii anticda monoclonal antibody hu moderatesevere psoriasis iii roaccutanaccutane isotretinoin new formulation severenodular acne nda filed xenical orlistat treatment prevention type diabetes iii xenical orlistat weight loss weight management children iii dilatrend carvedilol severe chronic heart failure iii dilatrend carvedilol postmyocardial infarction iii activase alteplase catheter clearance nda filed xolair omalizumab allergic asthma seasonal allergic rhinitis nda filed tnkase tenecteplase iiaiiiacombination acute myocardial infarction iii nda new drug application genentech compound optin candidate forroche genentech compound developed andor marketed roche jointly developed roche trimeris jointly developed genentech xoma genentech project jointly developed genentech tanox andnovartis studies conducted cor therapeutics scheringplough merck aventis pharmaceuticalsby combining strong inhouse rd focused seven broad range marketed products wellbalanced rd key therapeutic areas successful strategic alliances pipelinewe well equipped significant investments new technologies achieve stronger organic growth years aheadat time ensuring steady stream new drug candidates remain open opportunities future licensing agreementsacquisitions alliances help us reinforce jonathan knowles head global pharmaceutical research ourposition pharmaceuticals industry cular diseasesuch markers yield outlook well equipped important information course successful future expect sales major global pharmaceutical com diseases efficacy growth pharmaceuticals divi pany world leader invitro thedrugs used treat sion accelerate diagnosticswe unique position recently launched products benefit emerging revolu investing future roche tamifluxenicalmabtherarituxan tion medicine exploiting syner invested billion swiss francs herceptin xeloda impor gies application cutting pharmaceutical rd alonea tant growth driversas newly edge science complementary increase previous yearaddi acquired kytril wellestablished businesses tional research buildings became products cellcept neo operational year recormonin additionwe filed research centres penzberg germany approval pegasys united basel switzerlandrepresenting states europeand thedevelop investment around million ment new drugs ibandronate swiss francs sitethese new hiv fusion inhibitor facilities improve latestage clinical testing efficiency research anddevel progressing well opment efforts united states remains worlds alliance decode genetics important pharmaceutical mar iceland comprehensive ketwhich intend expand cluster important collaborations presence futurein bioscience companies univer expect see additional us sales sities produced important generated bythe rollout two new results included productspegasys valcytand identification gene linked acquisition kytril expanded schizophreniaproviding first labelling xenical manage genetic target development ment type diabetesa major new new diagnostic therapeutic indicationtheupcoming launch approaches diseasein addition xeloda europe continued gene locations identified growth otc brands also several risk factors causing contrib expected helpstrengthen uting strokealzheimers disease pharmaceuticals business osteoporosis peripheral arterial occlusive disease pharmaceuticals growing number people infected hepatitis c virus highly sensitive extremely reliable amplicor hcv tests enable physicians like dr k ofaachen germany detect infections virus early monitor patients responses treatment number international programmes underway roche develop optimal diagnostictherapeutic combinations viral diseases example currently working improved diagnostic tools assist interferon treatment hepatitis cdiagnostics division brief millions chf change sales patient care laboratory systems molecular systems molecular biochemicals ebitda operating profit rd expenditures employees adjusted basis diagnostics diagnostics division maintained strong growth previous years background sluggish expansion global invitro diagnostics market market share gains another yearonyear increase operating profit margin enabled us extend global market leadership sustained dynamic growth molecular diagnostics another exceptionally good result diabetes monitoring products main contributors strong performance success ful integration avl medical instruments made us market leader rapidly growing hospital emergency diagnostics market explosion knowledge resulting mapping human genome opens exciting possibilities new diag nostic products growth diagnostics ebitda rose million swiss francsa systematic focus customer needs aboveaverage sales gains four business seg ments contributed record result patient care impressive progress diabetes monitoring emergency diagnostics roche patient caresup plier worlds leading products people diabetes innova tive pointofcare diagnostic testscon tinued successful track record previous yearsparticularly dia betes blood glucose monitoring sec torwith sales billion swiss francs globally marketed accuchek line products blood glucose monitoring roche groups topselling brandtotal sales roche patient care inlocal currencies againthe accuchek advan tagecomfort strip blood glucose meter major driver sales growth global market technology leader human diabetes monitoring businessat end roche launched accu diagnostics roche superbly placed translate chek compactthe worlds first fully results genomics proteomics research tests automatic blood glucose metermuch simpler use test strips meet specific needs inserted cartridge automatically heino von prondzynski head diagnostics division prepared positioned excep tionally accurateitoffers significant improvements forpatients market leadership extended slowgrowing market roche consoli clinical tests carried dated leading position major point care becoming increas segments thanks innovative business ingly important worldwide means models efficient marketingsales making healthcare delivery diagnostics division advanced efficient controlling coststhe local currencies acquisition ofaustriabased avl med million swiss francsoperating ical instruments roche graz profit million substantially expanded product swissfrancsand divisions portfolio highpotential hospital diagnosticspointofcare segment rapid diagnosis moderate market growthincreasingly emergency intensive care hospitals highvolume clinical medicine time made laboratories asking integrated roche market leader area highthroughput systems improve costefficiencyby responding major new product launches new requirements automated pointofcare segment included car pre postanalysis processingan diac ddimer opti rcardiac expanded range test menus ddimer new assay allows doc innovative developmentswe tors rule pulmonary embolism enhanced already strong deep vein thrombosis rapidly market position reliablyit used roches cardiac readera proven instrument clinical chemistry segment diagnosing damage heart muscle thenew cobas integra analyser opti ra blood gas analyser devel launched towards end opedby avl medical instruments thanks outstanding userfriend employs reusable test cassettes simplify decentralised testing oper total sales division millions chf ating rooms also environmen tally friendly economical optimal userfriendliness key objective research dia betes care segmentamong thingswe developing systems require smaller blood samples combine sampling blood glucose determination single stepa long term goal development sys tems enable noninvasive liness highprecisionthe new blood glucose measurementwithout system establish need bloodsamplingin market quickly smaller hospital pointofcare segment integra demand efforts focused developing remained strong second year highly integrated diagnostic systems launch despite tough competition emergency intensive care market response highvolume departments laboratory segment modular analyticsan individually configurable laboratory systems growing trend highthroughput system combining costeffective analysers roche clinical chemistry immunodiag laboratory systemsthe worlds leading nosticswasvery positive supplier integrated analytical sys tems clinical laboratoriesposted sales elecsys analysersfor het sales gains local currencies erogeneous immunoassaysonce amid fierce competition showed aboveaverage growthin diagnostics hematology cooperation puted market leader gene amplifica japanese company sysmex ex tionbased molecular diagnosticsthis tended additional marketsroche reflected six yearssustained rapid held market share coagulation growthwhich continued automated urinalysis segments impressive local currency increasethese gains also result work research facilities strong demand products based cooperation japanese highly sensitive polymerase partnerhitachiroche laboratory chain reaction pcr techniquepcr systems pursuing projects consol enables direct detection pathogens asiapacific south america molecular biochemicals molecular systems sales region sales business unit north america europe africa patient care laboratory systems idate full range analytical systems individual genetic variations even common platformthis involves minute quantities sample material harmonisation consolidation several technologies single work tests detection ofaids station integration sample han hepatitis infectious diseases dling data managementpermitting regarded gold standard allinone solutions indi molecular diagnostics continue vidually configured line cus rank among topselling products tomersneedswe also working despite strong competitionamplicor expanded assay menus elecsys hiv monitorwhich measures hiv linefocusing initially tests concentrations bloodremained infectiousdiseasesthe main objective far frequently used quantita joint proteomics research initia tive aids testtests sexually trans tivewith pharmaceuticals division mitted diseases screening blood see p development new productsboth segments potential diagnostic markers various types developmentposted cancermetabolic inflammatory average growth disorders cardiovascular diseases marketing applications filed molecular systems expanding united states two pcrbased tests gold standard new segments monitoring aids treatmentboth market share already successfully launched roche molecular systems undis marketstwo qualitative hepatitis c diagnosticsdiagnostics division research lab patients molecular biochemicals molecular systems reagents systems gene analysis used biomedical pcrbased assays automated analysers detecting research investigate causes predisposition infectious diseases cancer cardiovascular disease specialty biochemicals industry hereditary disorders monitoring treatment investi gating genetic causes disease reagents molecular cell biology lightcycler amplicor tests cobas amplicor ampliscreen ampliprep lumiimager magna pure lc rts patient care laboratory systems diagnostic products pointofcare testing patient integrated analytical systems clinical laboratories selfmonitoring blood glucose meters accom complete solutions immunodiagnostics work areas panying data management software systems coagula laboratory network solutions reagents clinical chemistry tion monitoring blood gas analysis electrolyte determi immunodiagnostics products coagulation testing nation urine test strips rapid drugsofabuse screening hematology automated urinalysis tests accuchek softclix camit cardiac reader opti omni cobas integra rochehitachi cobas core elecsys stago molecular systems molecular systems reflotron comburtest coaguchek ontrak sysmex miditron supertron testswere submitted fda pcr marketto secure roche objective translating results accorded fasttrack review molecular systemslongterm success human genome project status decided invest new diagnostic products individually stateoftheart production facilities tailored healthcare solutions licensing agreements concluded new jersey entire range usbased chiron corporation covering pcrtests molecular biochemicals fore hiv hepatitis c patent rights front genomics proteomics marked end protracted litigation cobas taqmana nextgeneration sales roche molecular biochemi set stage additional analyser speed simplify calswhich manufactures reagents future growthin additionin mid routine pcrbased testing high systems industrial biomedical signed agreement throughput environmentsis researchwere local curren us company applera allows advanced developmentwe also ciesdriven mainly dynamic growth roche applera develop stepping rd activities german us marketsmarket market products pcrbased aim significantly expanding share gains united states applicationswe expect range pcr testsroche molecular particularly strong enhance potential growth systems vigorously pursuing diagnostics good result due primarily roche molecular biochemicals thus sales roches innovative lightcycler continuing successful transforma systemlaunched two years ago tion reagent manufacturer far exceeded expectations developer supplier innovative lightcycler employed principally systems breakthrough fields ingenetic research diagnostics genomics proteomicsof particu pcrbased amplification genetic lar significance launch materialthis product line ex rts worlds first panded end automated system cellfree protein launch magna pure lca module expressionuntil expression offers fully automated nucleic proteins coded particular genes acid isolation various sample important research materials realtime detection causes disease lightcycler areashas difficultthe required proteins could frequently syn thesised quickly enough sufficient quantitiesthe new rts fore play major role rapidly developing proteomics market integrated healthcare benefits patients collaboration virology pharmaceuticals diagnostics divisions agreement signed early continued produce excellent results marketplace prionicsa swiss biotech companywe handle worldwide stateoftheart treatment algorithms defined hiv part several distribution screening test comprehensive programmes viral load monitoring viral resistance genotyping cattle disease bsethe testwhich therapeutic drug level monitoring combined use retrogram decision support wasdeveloped prionicsis already software analyse results already helping physicians chose antihiv drug use many european countriesthe combinations highest probability success promotes effective use agreement also provides forcollabora roches medicines hiv viracept invirasefortovase tion developing tests used detect bse live animals influenza programme marks real breakthrough early detection treatment joint development diagnostic tests common viral illness combined use realflu surveillance system rapid creutzfeldtjakob disease man influenza test innovative drug tamiflu ensures targeted effective influenza therapy additional strategies tools developed improve detection moni units research efforts continue toring local influenza outbreaks make diagnosis treatment even effective focus developing new applications pcrbased diagnosticsespecially clinical trials pegasys hepatitis c amplicor hcv monitor shown fields oncologyinflammatory areliable means assessing clinical benefit three months therapy means disease cytologyanother key treatment reviewed early patients whose predicted probability response areais gene function analysisa logical limited continued greatest potential therapeutic benefit patients extension human genome showing response project undertaking would havebeen unthinkable without major roche research sites equipped resources identify inte high throughput automation made grated healthcare opportunities early stages drug discovery development possible pcr technologyroche exploit improving treatment outcomes molecular biochemicalsrapidly evolv diagnosticsing strategic role engine set continue pioneering innovation division reflects scientific work fieldone trend work contacts forefront expected stimulate additional sales new developments areas segment rising demand diagnostics products screen donated blood derivativesroches highly optimally positioned continued accurate pcr tests already used dynamic growth diagnostics test substantial proportion divisions four business units blood plasma productsour new excellent basis growth ampliprep system pcr sample preparationscheduled launch roche patient care enormous soonbrings us close objective growth potentialfuelled mainly fully automated pcr testing rapidly expanding diabetes marketin hospital pointofcare segment immensely promising fields expanded product portfolio know genomics proteomics fact roche con main focus roche molecular bio trols entire value chainfrom rd chemicalswhose objective right sales marketing translate research findings give us significant advantageroche products routine diagnosis patient care expand product range launch overallwe intend step two innovative blood gas elec research effortswith clear focus trolyte analysers highgrowth marketsour activities directed towards creating new launches additional userfriendly markets generating additional instrumentsexpanded assay menus business new services exam costcontrol productivity pledeveloping solutions enable measures positive impact networking data generated several roche laboratory systemsperfor different locations hospital mance highly competitive business laboratoryat patients bedside environmentin immunochemistrythe etcour top longterm priority launch elecsys e module thecreation intelligentuserfriendly scheduled early con systems services tribute sustained aboveaverage growththe new module enhances existing system platform combining preanalyticsclinical chemistry immunodiagnostics single work station worldwide first growth knowledge genetic basis disease also opening range new business opportuni ties roche molecular systems diagnostics vitamins play crucial role balanced nutrition number factors fromphysical exertion emotional stress smoking illness pregnancy increase persons vitamin requirements roche vitamins added multitude food products beverages vitamins receiving attention today ever fromthepublic large researchers roche consumer health aunit pharmaceuticals division leading supplier vitamin products broad range brands thatincludes supradyn berocca redoxon elevitvitamins fine chemicals division brief millions chf change sales vitamins carotenoids fine chemicals ebitda operating profit rd expenditures employees adjusted basis vitamins fine chemicals vitamins fine chemicals division recorded significant volume growth major product segments however divestment medicinal feed additives business continued downward pressure prices led decline value sales result operating profit despite efficiency gains rigorous focus costs expanded leading market position helped new product launches uncompromising focus needs key global accounts investments modern manufacturing processes aimed raising productivity important milestone marked completion new production facilities biotin vitamin b grenzach germany formulation vitamins carotenoids sisseln switzerlandthese capital investments part systematic effort upgrade divisions plants latest technological standards optimise manufacturing capacity consolidate production key vitamins suitable sites worldwide vitamins fine chemicals medicinal feed additivessales revenues advanced swiss francsthe impact pricing pressures margins partially offset increased sales volumes improvements operational efficiencyas result operating profit ebitdadeclined million million swiss francs respectivelythese figures equivalent sales global demand vitaminscarot enoids citric acid remained theincrease ourvolume sales expanded signifi cantly faster marketwith doubledigit growth recorded astaxanthinvitamin b pantothenate biotincitric acidpolyunsaturated fatty acids feed enzymeswe scored particularly strong market share gains highly competitive citric acid market production capacity citric acid plants tienen bel gium wuxi china expanded last year moved reinforce thanks economical highquality products position one worlds leading suppliers segment food pharmaceutical cosmetic feed industries ideally equipped continue expanding competitive pressures mounted pro ducers continued consolidateby market leadership contrastthe prices several key vita markus altwegg head vitamins fine chemicals division minsincluding vitamins ec b stabilised second half slipping earlier yearin case biotinprices even rose mod good performance challenging estly response strong market marketplace sales vitamins demand fine chemicals division slightly yeardeclining following sale medicinal local currencies million feed additives business alpharma swiss francsas result price erosion focus resources divestment medicinal ourcore businesses vitamins feed additives businesscompleted carotenoids fine chemicals early may excluding sales vitamins today account roughly vitamins fine chemicalsonehalf divisional salesin promising growth sectors countriesand already contributed attention centred particularly needs major industrial customers appreciably good sales growth rollout new products lutein among thingsthis involved product categoryto enable us carotenoid helps maintain eye organisational changes allowing us serve animal nutrition industry healthand highly standardised natural support customers even effec even better futureconstruction source vitamin eand phytasea feed tively developing tailormade prod begun vitamin premix plant enzyme codeveloped novozymes ucts markets pet foods deinze belgiumand increases bioavailability decision made build additional phosphorous animal feedsthus pivotal role animal nutrition sales feed premix facilities spainhun reducing environmental impact carotenoids animal nutrition garykorea vietnam costs animal productionwe industrythe divisions largest market asiapacific food industry cosmetics pharmaceuticals sales region sales customer segment north south america europe africa animal feeds also launched vitamin b manufactured total sales division millions chf fermentationwhich supply significantly improved product forms use animal feedsfoods pharmaceuticals starting growth strategy augmented strategic alliance novozymes aimed developing major new feed enzyme adjusted basis products benefits livestock health environmentin markets roche sell products covered alliance segmentwere exceptionally goodthis key supplier food phar due primarily continued strong maceutical industries sales tailoring products customers demand astaxanthin aqua foodprocessing industry also needs roche supplies broad range culture sector norway chile substantially volume termshelped products contribute significantly canthaxanthin canadabiotin growing trend fortify staple improved nutrition healthour sales upfuelled nutrients foods vitaminsdemand main customers producers pro important role maintaining health functional foods stimulated cessed foodsanimal feedspharmaceu performance livestock pets increasing consumer awareness ticals cosmeticsin new phytaseronozyme pwas importance certain nutrients even tighter operational focus approved marketing number healthby contrastsales phar vitamins fine chemicals maceutical industry fell slightlylargely life expectancies altering peoples weak demand us ideas attitudes nutrition dietary supplements sectorwe thus opening significant market also expanded global network opportunitieswe therefore specialised premix plants serving stepped search active com food pharmaceutical industries ponents natural products order strengthen position shown beneficial effect leading supplier vitamins onhuman healthour development segmentsa new facility completed pipeline includes products help el salto mexicoand additional prevent osteoporosislower cholesterol plants supplying industries prevent cardiovascular disease built south africa china improve cognitive functionzeaxan thina close relative betacaroteneis volume sales rose cosmet ready market ics segmentthanks particularly launched complement lutein brisk demand vitaminsthe market zeaxanthin helps protect vision sunscreens continues expand reducing risk agerelated eye consumers become increasingly aware disease macular degeneration importance protecting skin ultraviolet ultraviolet supplying market b lightsales ultraviolet sun expanded range new products screen parsol heavily disease prevention one divi affected loss patent protec sions prime goalshere efforts tion europe willbenefit sciences ever deeper understanding role sound research development identi nutrition healthadvances fying exploiting new market area facilitated use opportunities research develop latest technologies molecular ment activities focused optimising geneticsa field roche manufacturing processes terms leaderthese technologies finally qualityproductivity environ making possible identify mental performance developing underlying causes degenerative new products customers every diseases develop innovative segment serve approaches combating developing innovative product formu investments targeted maintaining lations one divisions core cost leadership investments prop competenciesnewhigherdose vita ertyplant equipment totalled min formulascombinations vita million swiss francs com mins new betacarotene pared million swiss francs products developed meet theprevious year part customersneeds even better systematic effort optimise capacity divisional production facilities trend towards functional foods worldwide concentrate manufac illustrateslifestyle changes longer turing best locationsthe aim vitamins fine chemicalsisto achieve substantial additional task force sight life savings reinforce position years roche actively engaged fight vitamin deficiency lowestcost supplier key among children developing world founded task force sight products life provides vitamin free charge nutrition intervention programmes funds research projects shares technical knowhow sight life important milestone realising involved nearly projects large small africa asia latin america strategy completion new activities included distribution roughly million free vitamin capsules sup production facilities biotin port training programmes health workers together vitamins fine vitamin b grenzach germany chemicals division sight life also supported programmes promoting representing investment tification staple foods since inception task force received million last three years roughly million swissfrancs funding roche deutschmarksin dalry scotland expanding capacity upgrading vitamin c manufacturing processes customers new growth opportuni cost million pounds ster ties established core businesses lingthe first phase construction vitaminscarotenoids fine chemi completed spring calswe expect see continued strong startup new facilities carotenoid demand productsparticularly vitamin powder formulations aquaculture functional food sisseln switzerland established segmentsnewly launched products site divisional centre excel naturalsource vitamin e lence powder manufacturing tech lutein new feed enzymewill nologysisseln also site stimulate additional sales growth new vitamin e plant annual capacity tonnesthe facility onehalf research development completed three years expenditure allocated maintain cost approximately million swiss expand cost leadership vita francs min production long term within next ten years want october opened one cut costs manufacturing worlds largest vitamin b factories main products half help shanghaiin line strategic aim radically new production technologies expand divisions chi programmes introduced last year nese manufacturing baseadditionally make regional marketing organ new citric acid plant built isations efficient also help us wuxiit begin manufacturing achieve profitability targets chinas domestic market competitive edge research export second quarter production knowhow expanding global presenceparticularly solid basis profitable growth emerging markets ofasia vitamins fine chemicals division latin americawe ideally equipped continued strengthen opera maintain leadership com tional structureswe streamlined petitive attractive global market product portfolio concen significant potential growth trated resources even key vitamins fine chemicals human resources medicinal feed additives busi nessverystrong sales growth acquisition ofaustriabased avls medical instruments business led amarked increase headcount diagnostics divisionavl medical instrumentsemployees rapidly integrated divisionand success determined large measure thepersonnel adjustments needed toeliminate duplication imple qualifications motivation employees mented socially responsible continuing promote performancebased fashionthe cost wagessalaries andemployee benefits totalled culture intend company best people million swiss francs want work new technologies ongoing realign daniel villiger head corporate services ments response changing market needs continue make tough de mands flexibility dedica continuing development makes tough tionof employeesdisplaying demands end high levels motivationskill pro roche group employed people fessionalismthey met chal worldwidethis less lenge rapid structural change figuredue spinoff mastering increasingly complex tasks fragrances flavours division enhancing roches per mid divestment formance vitamins fine chemicals division human resourcesheadcount division year end itsduethis supported identifying change change critical performance areas creating pharmaceuticals individual development plans diagnostics employeeswe reward high achievers vitamins fine chemicals performancebased salary compo fragrances flavours nentsa system continued others toextend additional management roche group levels roche offers wide range attractive career opportunities headcount region year end employees development potential europe aboveaverage commitment switzerland north america executive committee decided latin america continue groupwide workshops asia conducted explain dis africa australia oceania cuss roches corporate principles total issues relating behaviour busi nesswith addition new topics subjects covered next continual expansion leadership europewide programme designed phase protection personal skills professional abilities promote international experience shar datathe use roche electronic com social competence ing transfer knowhowthe munication toolsand business stepped efforts provide vitamins fine chemicals division integritythe programme designed employees firstrate opportunities revamped management develop impart rules behaviour busi personal professional develop ment succession planningwith ness enable roche employees mentthis done primarily offer main focus preparing successors perform tasks way ing challenging management positions key posts exemplary every respectwe firmly local international levelsmany believe business practices based involving complex project september saw groundbreak ethical social also management tasksroche encourages ing ceremony roches new interna environmental responsibility see continuous assessment training tional training conference centre safety environmental protection development needs middle senior managersroche forum p cornerstone commer senior managers prepare buonaswhich established cial success postsin roche initiated scenic buonas peninsulalake zug groupwide programme indi switzerlandthe new complex vidual focus develop leadership incorporate conference areameeting skills collaboration london roomsa restaurant accommo business schoolseveral hundred dation wingif ambitious timetable senior managers roche affiliates metwe expect centre oper worldwide take part two ational early part programmewhich run similar programme commitment performance culture implemented extensively phar ethical business practices maceuticals divisionin autumn roches management culture per diagnostics division started formancebased give excellence human resources safety environmental protection pation chemical industrys world wide responsible care programme andother initiativeswe taking initiative efficient solutions helping improve community acceptance roche production locationsin sowe conscious dynamic interdependence safety products processes economicenvironmental social issues protection employees environment unwanted effects activities essential given nature manufacturing activitiesour principal aim pro roches longterm success mote ecoefficiency continually hans knzi head corporate safety environmental protection improving existing production processes replacing fun damentally new onesaccordingly sustainable development inno integrated safety environmental vativeglobally active healthcare group protection controls accounted roche committed putting substantial part roches total se principle sustainable development expenditure practice responsibly appro priatelywe intend maintain accidents incidents already high healthsafety envi roche remained free major ronmental protection se standards incidentsunfortunatelyhoweverwe continually improve performance report serious accident areasas shown partici one plants china claimed safety environmental protectionlife young employeethe first fatal safety environmental protection expenditure millions chf ity group facility many yearsit caused human errora factor investment even sophisticated safety operating costs measures never completely offset total expenditure two incidents involving firesone factory morocco coalfired power plant china organisations bodies one french produc another significant reduction including oecdilo cefic tion facilitieswhich resulted prop achieved emissions volatile working improve safe manage erty damage organic compounds vocsthough ment chemicalswe particularly emission levels vary site active programmes focus overallthe number occupational tosite owing varying production high production volume chemicalsin accidents remained previous volumesour contributions envi past two years chemical indus years low levelan achievement ronmental protection also received try launched number interna trainingcontinuing education public recognitionimplementation tional initiatives speed rigorous se audits throughout newecoefficient synthesis activities improve knowledge group certainly made important antiviral agent ganciclovir enabled chemicals used worldwide large contribution se audits conducted reduction wastefor quantitiesin additionroche roche facilities countries facility boulder colorado received major contributor global chemi confirmed groups uniformly presidential green chemistry cal industrys longrange research ini highhealthsafety environmental challenge awardin mexico tiativewhich aims increase standardsthis positive trend facility cuernavaca received understanding ways reflected awards roche facilities clean industry award chemicals interact human factory clarecastle ireland body environment received awards national irish total volume chemical waste safety organisation depart declined far steeply produc ment enterprisetrade employ tion volumesuccessful implementa ment logging one million man tion policy eliminating sub hours without lost worktime due stances contribute depletion accidentsand plant florence ozone layer replacing north carolina similarly hon alternative solutions continued oured us occupational safety roche took important step towards health administration goal sustainable development introduction fermenta successful environmental protection tion process vitamin b production measures good environmental thanks new processconsump protection record previous years tion nonrenewable raw materials maintained overallalthough problems reduced voc emissions atmospheric emissions led emissions water investigation authorities one moreoverthe resulting waste com group companyenergy consumption postableallowing natural recycling declined slightlyin step modest drop production volumeby con commitment sound environmental trastco emissions increased policy many years roche con yearfollowing acquisition tributed expertise international safety environmental protection finance roche achieved record net income chf billion increase previous year operating result enhanced placing genentech shares market contributed chf bil lion group operating profit chf billion group net income addition finance treasury operations contributed strong net financial income chf billion including gains sale labcorp shares adjusted basis excluding effects items changes accounting policies fragrances flavours business spun june group net income increased result strong cash flow roche three years corange acquisition become net creditor net liquidity position chf billion ratio equity minor ity interests total assets improved financefinancial review highlights millions chf figures reported figures reported financial statements adjusted basis change change sales ebitda operating profit net income record results roche group achieved record results consolidated sales reached billion swiss francs increase previous year ebitda increased billion swiss francs operating profit reached billion swiss francs rise compared net income rose billion swiss francs results driven higher operating financial income substantial gains sale genentech labcorp shares adjusted basis results roche group also reflect strong performance group sales rose billion swiss francs ebitda increased billion swiss francs operating profit billion swiss francs net income billion swiss francs adjusted figures presented improve comparability current future results given shown continuing basis without fragrances flavours business adjust accounting effects various special items changes international accounting standards description adjustments given roche recorded record profits net income rose previous year billion swiss francs henri b meier chief financial officer december doubledigit sales growth diagnostics sales growth pharmaceuticals reduced due patent expiry generic competition reported group sales growth influenced spinoff givaudan june adjusted basis ie excluding sales fragrances flavours roche group achieved growth rate swiss francs local currencies furthermore sale ofthe medicinal feed additives mfa products may influenced topline results excluding mfa fragrances flavours group posted sales growth swiss francs local currencies financial review growth rates swiss francs local currencies sales diagnostics division outpaced market sales patient care molecular systems molecular biochemicals grew doubledigit rates local currencies pharma sales rose swiss francs local currencies good performance certain established new products mabtherarituxan herceptin neorecormon cellcept roaccutanaccutane partially offset generic competition versed ticlid united states patents expired strong start sales xenical levelled sales vitamins finechemicals division increased swiss francs declined local currencies excluding mfa products sales volumes continued grow strongly price levels ayear decline average stabilised increase ebitda operating profit group ebitda increased billion swiss francs operating profit increased billion swiss francs main drivers strong result increase gross profit another substantial gain sale genentech shares absence unprovided expenses settling vitamin case gross profit margin remained stable mar keting distribution costs grew faster sales exploit market potential established new products net operating income reflected gains continuing realignment product portfolio adjusted basis ie excluding special items changes accounting policies fragrances flavours business ebitda rose billion swiss francs operating profit billion swiss francs roche far highest amortisation charge large pharmaceutical companies result acquisitions instead mergers use international accounting standards amortisation charge billion swiss francs sales compared sales main competitors ebitda margins diagnostics pharmaceuticals remained practically unchanged vitamins ebitda margin declined slightly result lower average prices givaudan spinoff completed june fragrances flavours division listed swiss exchange independent company name givaudan shares givaudan distributed special dividend holders roche shares nonvoting equity securities onefor onebasis annual impact spinoff results roche group shown adjusted figures reduction sales operating profit net income acquisition kytril strengthen roches oncology portfolio december roche acquired global rights kytril billion us dollars smithkline beecham connection merger glaxo wellcome kytril achieved net sales million swiss francs roche also sold smithkline beecham exclusive rightsto coreg united states canada million us dollars substantial gain sale genentech shares march group sold million shares genentech public offering yielding proceeds billion us dollars resulting pretax gain incidental costs billion swiss francs roche holds genentech corresponds approximately majority holding acquired financial reviewmajor steps settling vitamin case united states roche completed two major steps settling vitamin case united states march us federal judge approved overall settlement agreement class action suit brought us buyers bulk vitamins several customers class action decided opt overall settlement pursue claims group individually october overall agreement indirect customers endconsumers united states announced outside united states european commission issued astatement objections july producers bulk vitamins including roche global provisions recorded remain current best estimate total liability another strong financial result total financial income reached billion swiss francs strong positive result primarily driven net gains sales marketable securities including shares labcorp june labcorp called redemption entire convertible preferred stock part held roche portfolio investment conversion process roche realised pretax gain million swiss francs october roche reduced holding labcorp realising pretax gain million swiss francs gain october sale excluded adjusted results capacity generate high cash flow solid financing highly flexible well equipped future anton affentranger chief financial officer since january financial condition strengthened group achieved impressive cash flow gross cash flow group ebitda increased billion swiss francs reflecting improvements operating result including gain sale genentech shares furthermore improvement work ing capital turnover financial income contributed substantially net liquidity strength ened billion swiss francs total year december net liquidity amounted billion swiss francs compared net debt billion swiss francs december ratio equity minority interests total assets increased atyearend end offsetting impacts new revised international accounting standards several new revised standards issued international accounting standards committee became effective january effects changes accounting policies regarding business combinations intangible assets amount billion swiss francs largely offset impact new standard impairment assets billion swiss francs accounting effects major acquisitions since reported aconsistent manner financial review consolidated income statements millions chf figures reported figures reported financial statements adjusted basis change change sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets operating income expense net gain sales genentech shares vitamin case genentech legal settlements operating profit financial income expense net profit taxes income taxes profit taxes changes accounting policies income applicable minority interests share result associated companies net income diluted earnings per share nonvoting equity security chf adjusted resultsthe consolidated results significantly influenced various special items also changes international accounting standards improve comparability current future consolidated results adjusted figures calculated years used internal management business helpful reviewing trends groups results adjusted results shown continuing basis results fragrances flavours division excluded givaudan spinoff already taken place january sales vitamins fine chemicals division fragrances flavours division reclassified sales third parties adjusted results also exclude gains sales genentech shares gain sale labcorp shares inoctober costs vitamin case genentech legal settlements adjusted results show recurring accounting effects new revised international accounting standards became effective january acquisition remaining outstanding shares genentech already taken place beginning adjusted figures exclude charges recorded second half relating fairvalue adjustments inventories associated genentech acquisition adjustments also led corresponding modifications income taxes income applicable tominority interests minority interest figure calculated participation genentech december applied throughout whole analysis adjustments given explanations adjusting items given notes consolidated financial statements financial reviewsales adjusted basis millions chf change change local division chf currencies pharmaceuticals diagnostics vitamins fine chemicals total sales gross profit gross profit increased million swiss francs billion swiss francs gross profit margin remained adjusted basis ie excluding primarily fragrances flavours gross profit reached billion swiss francs increase billion swiss francs onthis basis gross profit margin also remained stable gross profit margin improved favourable change division mix higher share highmargin busi nesses productivity improvements divisions however offset contin ued pressure prices particular vitamins fine chemicals anda new generation ofproducts diagnostics increased production service costs marketing distribution marketing distribution expenses increased million swiss francs billion swiss francs adjusted basis ie excluding fragrances flavours marketing distri bution expenses rose billion swiss francs billion swiss francs major factors involved increased efforts pharmaceuticals build market xenical tamiflu increased support new oncology products premarketing expenses upcoming product launches factors increased marketing spend diagnostics foster leading position industry build new markets research development rise research development costs almost exclusively attributable genen techs inlicense collaboration agreements increased spending laterstage clinical trials excluding genentech research development costs remained level research development costs percentage sales group level stable pharmaceuticals account groups research development expenses remained administration administration costs grew adjusted basis ie excluding fragrances flavours increase slightly greater growth sales mainly result increased legal costs due competitive conditions governmental inquiries offset ting savings improved processes amortisation intangible assets significant increase amortisation expenses primarily driven halfyear amortisation intangible assets goodwill resulting acquisition remaining outstanding genentech shares june adjusted basis increase amortisation intangible assets primarily due foreign currency effects impairment longterm assets adoption new international accounting standards resulted impairment charges billion swiss francs relating intangible assets acquired prior impairment entries resulted net impairment credit million swiss francs shown theadjusted results financial review operating income expense net operating income expense net increased billion swiss francs mainly due higher gains ongoing realignments product portfolio higher royalty income despite increased royalty restructuring expenses operating profit operating profit rose billion swiss francs primarily driven increase gross profit billion swiss francs gain sale genentech shares unpro vided expenses vitamin case operating profit adjusted basis increased billion swiss francs margin sales adjusted basis declined divisional results adjusted basisin millions chf vitamins pharma fine ceuticals diagnostics chemicals group year ended december divisional sales third parties ebitda sales operating profit sales year ended december divisional sales third parties ebitda sales operating profit sales ebitda earnings interest financial income tax depreciation amortisation including impairment measures gross cash generation divisions divisional operating profit margins furthermore reflect different fixed asset intensities businesses acquisition history ebitda margin pharmaceuticals division remained higher marketing costsfor xenical tamiflu new oncology products premarketing expenses upcoming product launches offset higher sales improved gross profit margin andby gains continuing realignment product portfolio diagnostics division maintained ebitda margin higher marketing efforts led correspondingly higher sales operating profit margin increased percentage point strong longterm competitive pressure vitamins fine chemicals business con tinued however division able offset sales price decline extent furtherproductivity improvements volume increases ebitda decreased one percentage point result consists costs corporate headquarters increased substantially due restructuring costs relating basel institute immunology vol untary solidarity contribution holocaust victim assets litigation swiss banks litigation financial reviewfinancial income expense net total financial income expense net showed substantial increase billion swiss francs key factors profits achieved marketable securities portfolio despite weak stock markets together gain sale labcorp shares reduced groups participation gain portfolio investment labcorp convertibles higher net liquidity available interest income increased substantially increase largely compensated rise interest expenses resulting additional debt increases discounted value provisions net result foreign exchange transactions also improved compared previous year even exclusion gain theoctober saleof labcorp shares total financial income expense net rose analysis components given note consolidated financial statements net income net income rose billion swiss francs represents return sales adjusted basis increase amounted balance sheet millions chf change longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities total equity minority interests liabilities one notable factors development groups balance sheet year spinoff givaudan excluding assets billion swiss francs liabilities bil lion swiss francs roche groups balance sheet significant development acquisition global rights kytril billion us dollars added intangible assets also change accounting policy group reclassified reduction equity billion swiss francs equity instruments previous years reported marketable securities record earnings fed genentech labcorp share sales strong results ongoing activities largely responsible turning net debt position billion swiss francs start year net liquidity position billion swiss francs end also helped raise groups ratio equity minority interests total assets period knock bonds repaid maturity helveticus convertible bonds also exercised consequent reduction groups borrowings nevertheless offset issue sumo lyons bonds implementation new revised international accounting standards intangible assets business combinations january resulted increase billion swiss francs intangible assets however reduction intangible assets similar magnitude arose follow ing implementation new standard impairment assets date net effect balance sheet minor changes purely accounting nature impact groups cash flows financial review cash flows millions chf operating activities income taxes income taxes paid activities operating activities financing activities investing activities net effect currency translation cash increase decrease cash cash flows operating activities income taxes increased billion swiss francs due improved operating result better working capital performance reduced outflows respect vitamin case restructuring income taxes paid considerably higher mainly due genentech labcorp share sales financing activities cash flows benefited billion swiss francs proceeds issue sumo lyons iv bonds exceeded outflows theknock helveticus bonds meanwhile billion swiss francs proceeds genentech labcorp transactions partly used kytril acquisition billion swiss francs additions property plant equip ment billion swiss francs remainder reinvested net purchases marketable securities give net cash outflow investing activities billion swiss francs foreign exchange rates exchange rates swiss franc december average december average december usd eur gbp jpy compared us dollar average stronger swiss franc theeuro around weaker net effect differing exchange rate patterns groups sales positive percentage points us dollars strengthening swiss franc yearend basis contrasted theweakening euro japanese yen divergence trends tended mitigate effects groups balance sheet financial reviewchfusd exchange rate j f j j n introduction euro introduction euro presented various opportunities streamline conduct business regard systems business processes systems european group companies adapted handle eurodenominated transactions companies con cerned able deal dualcurrency transactions transition period located emu countries converting euro accounting purposes course financial review consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement millions chf year ended december sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets operating income expense net gain sales genentech shares vitamin case genentech legal settlements operating profit financial income expense net profit taxes income taxes profit taxes changes accounting policies income applicable minority interests share result associated companies net income basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security chf consolidated financial statementsconsolidated balance sheet millions chf december longterm assets property plant equipment intangible assets investments associated companies investments deferred income tax assets longterm assets total longterm assets current assets inventories accounts receivable trade current income tax assets current assets marketable securities cash total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm equity instruments retained earnings reserves total equity minority interests noncurrent liabilities longterm debt deferred income tax liabilities liabilities postemployment benefits provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable trade accrued current liabilities total current liabilities total equity minority interests liabilities pm pro memoria nonvoting equity securities nominal value see note consolidated financial statements consolidated statement changes equity millions chf year ended december share capital balance january december nonvoting equity securities genussscheine balance january december pm pm equity instruments balance january previously reported adjustment change accounting policies balance january restated movements year balance december retained earnings balance january net income dividends paid givaudan spinoff special dividend transfer net assets balance december reserves equity conversion options conversion option embedded sumo bonds currency translation differences balance january gains losses recognised year balance december balance reserves december total equity december pm pro memoria nonvoting equity securities nominal value see note consolidated financial statementsconsolidated cash flow statement millions chf year ended december cash flows operating activities net income nonoperating income expenses operating profit depreciation property plant equipment amortisation intangible assets impairment longterm assets effects genentech transactions vitamin case genentech legalsettlements adjustments noncash operating income expense increase decrease working capital costs vitamin case paid costs genentech legal settlements paid restructuring costs paid payments made defined benefit postemployment plans operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows financing activities proceeds issue longterm debt repayment longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid givaudan spinoff special dividend givaudan cash balances total cash flows used financing activities cash provided operating financing activities cash flows investing activities purchase property plant equipment intangible assets disposal property plant equipment intangible assets acquisition subsidiaries associated companies products divestments subsidiaries associated companies products interest dividends received purchases marketable securities net sales total cash flows used investing activities net effect currency translation cash increase decrease cash cash beginning year cash end year nonoperating income expenses consist following income statement items financial income expense net income taxes changes accounting policies income applicable minority interests share result associated companies consolidated financial statements notes consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international accounting standards using historical cost convention authorised issue board directors february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assump tions modified appropriate year circumstances change consolidation policy financial statements consolidated financial statements roche holding ltd acompany registered switzerland subsidiaries hereafter group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enter prise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights companys share capital companies acquired year consolidated date operating control transferred group subsidiaries divested included date divestment companies acquired resold consolidated classified assets held sale carried cost assets identified divestment following year reclassified assets held sale within current assets assets normally consist mainly inventories property plant equipment longterm assets investments associated companies accounted equity method com panies group exercises significant influence control isnormally evidenced group owns voting rights company interests joint ventures reported using linebyline proportionate consolidation method investments carried cost deducting appropriate provisions permanent impairment included longterm assets notes consolidated financial statementsforeign currency valuation assets liabilities group companies reporting currencies swiss francs foreignentities translated swiss francs using yearend rates exchange sales costsexpenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity exchange gains losses hedges nonswiss franc net investments intercompany balances longterm investment nature also taken equity divestment foreign entity cumulative currency translation differences relating foreign entity recognised income part gain loss ondivestment gains losses exchange arising group companies translation local reporting currency financial assets liabilities denominated foreign currencies settlement foreign currency transactions included income certain group companies maintain financial information group reporting purposes us dollars swiss francs euros functional currencies companies concerned effect exchange rate differences local currency usdollarswiss franc euro respect financial assets liabilities included income sales cost sales sales represent amounts received receivable goods supplied services rendered customers deducting volume discounts sales taxes cost sales includes cor responding direct production costs related production overhead goods manufactured services rendered research development research costs charged income incurred exception buildings major items equipment capitalised depreciated development costs also charged income incurred since criteria recognition asset notmet employee benefits wages salaries social security contributions paid annual leave sick leave bonuses options nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned group operates number defined benefit defined contribution plans throughout world cost year defined benefit plans determined using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return planassets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested pension assets liabilities different defined benefit schemes offset unless group legally enforceable right use surplus one plan settle obligations plan notes consolidated financial statements groups contributions defined contribution plans charged income statement year relate taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based onincome property capital taxes included within operating expenses financial expenses according nature provision income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries made current inten tion remit earnings deferred income taxes provided using liability method deferred tax conse quences recognised temporary differences tax bases assets liabilities carrying values financial reporting purposes deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows buildings land improvements years machinery equipment years office equipment years motor vehicles years investment grants similar assistance projects initially recorded deferred income inother noncurrent liabilities subsequently recognised income useful lives related assets repairs maintenance costs recognised expenses incurred borrowing costs capitalised assets acquired finance leases depreciated estimated useful lives payments made operating leases charged income straightline basis period lease inventories inventories stated lower cost net realisable value cost determined first firstout method cash marketable securities cash comprises cash hand time call current balances banks similar institu tions definition also used cash flow statement marketable securities shown lower cost market value notes consolidated financial statementsdebt instruments proceeds net expenses bonds issued warrants allocated bonds warrants proportion respective fair market values time issue discount arising low coupon rate represented difference prin cipal amount net proceeds charged interest expense life bonds obligations arising warrants issued debt instruments accrued period thewarrants outstanding meet maximum cash obligation date warrants exercisable provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated financial instruments gains losses forward exchange contracts options currency swaps used hedge potential exchange rate exposures deferred offset losses gains specific transactions hedged fee agreed establishing contract amortised duration contract interest differentials swap arrangements forward rate agreements interest rate caps used manage interest rate exposures recognised adjustments interest expense derivative financial instruments used trading purposes gains losses changes market value taken income arise certain covered call option contracts entered group require underlying securities lodged financial institutions involved arrangement fair values balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements international accounting standards several revised new standards issued international accounting standards committee interpretations standing interpretations committee became effective january listed effects described total recurring operating costs million swiss francs higher previous methods accounting recording effects changes accounting policy group follows allowed alternative retaining previous years figures reported ofdisplaying effect current years income statement property plant equipment provisions contingent liabilities contingent assets events balance sheet date adjustments necessary result implementations groups accounting policies previously reflected measurement prin ciples new revised standards share capital reacquired equity instruments groups holdings equity instruments recorded deduction equity original cost acquisition considera tion received subsequent resale equity instruments movements reported changes equity previously instruments recorded marketable securi ties treated equity instruments reported earnings per share would approximately higher instruments acquired primarily meet obligations may arise respect certain groups debt instruments notes consolidated financial statements impairment assets recoverable amount asset higher net selling price value use less carrying amount carrying amount reduced recoverable value reduction reported income statement impair ment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate previously value use calculated using cash flow projections undiscounted basis new standard required adopted prospective basis result effective january group recognised impairment charges million swiss francs relating acquired intangible assets reduction deferred tax liabilities million swiss francs also recorded giving net charge million swiss francs consolidated results groups previous accounting treatment impairment would arisen result impairment net book value intangible assets reduced amount impairment charge consequently amortisation million swiss francs lower would previous policy impairment entries arose year disclosed note intangible assets business combinations goodwill recorded intangible asset surplus cost acquisition fair value identifiable assets acquired goodwill fair value adjustments treated assets liabilities acquired company recorded local currency company patents licences trademarks intangible assets initially recorded fair value assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost intangible assets amortised useful lives straightline basis estimated useful lives major classes intangible assets follows goodwill years patents licences trademarks lower legal duration intangible assets economic useful life maximum years required implementation new revised standards group reviewed accounting previous acquisitions process included acquisitions genentech nicholas syntex tastemaker corange group recalculated goodwill assets liabilities arising significant acquisitions since adjusted carry ing values accordingly required new revised standards furthermore connec tion acquisitions made prior group reports intangible assets goodwill previously writtenoff equity recalculated goodwill assets andliabilities arising acquisitions thus accounting effects groups acquisitions reported consistent manner addition nonacquisitionrelated intangible assets reviewed ensure meet recognition measurement criteria ofthe new standard result january group recorded certain reclassifications adjustments original purchase accounting allocations reflect revised balances approximate amount amortisation january effects taxation balances minority inter ests follows notes consolidated financial statementsother deferred intangible income minority millions chf goodwill assets taxes interests total items previously recognised provisions charged expense transfers prior changes group organisation amortisation net deferred income tax effects net minority interests net credit income result change accounting policy carrying value intangible assets increased january consequently groups amortisation charge million swiss francs higher would previous policy increase diagnostics division new revised standards intangible assets business combinations applied groups net assets december would higher million swiss francs recurring operating costs would million swiss francs higher reported new standards consolidated financial statements new interna tional accounting standard financial instruments recognition measurement come effect standard requires financial assets financial liabilities recognised balance sheet including derivatives financial statements affected intro duction fair value accounting certain marketable securities investments derivatives certain marketable securities investments designated available sale group intends recognise changes fair value equity asset sold assessment impact standard groups financial position january reported consolidated financial statements adjustment retained earnings january restatement previously reported amounts year ended december result retained earnings increase approximately one billion swiss francs significant part relates investments fair value approximately one billion swiss francs higher carrying value december new international accounting standard investment property effective january expected significant impact groups financial statements international accounting standards continue developed revised future lead adaptations groups accounting policies coming years financial risk management financial risk management within group governed policies approved senior manage ment policies cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies also cover areas cash management investment excess funds raising short longterm debt notes consolidated financial statements deemed appropriate certain risks altered use financial instruments group management believes order create optimum value group desirable eliminate mitigate possible market fluctuations financial instru ments selectively used create optimise value group companies report details financial instruments outstanding financial liquidity position group treasury least monthly basis foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs transaction exposure arises amount local currency paid received trans actions denominated foreign currencies may vary due changes exchange rates many group companies income primarily local currency significant amount expen diture especially purchase goods resale interest repayment loans foreign currencies similarly transaction exposure arises net balances monetary assets held foreign currencies group companies manage exposure local level necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure help comprehensive data received monthly basis translation exposure arises consolidation foreign currency denominated finan cial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group hedges significant net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regular basis significant part groups cash outflows research development production admin istration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc rela tive currencies adverse impact consolidated net income similarly relative fall value swiss franc favourable effect results published swiss francs interest rate risk interest rate risk arises movements interest rates could adverse effects thegroups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk interest rates groups major debt instruments fixed described note reduces groups exposure changes interest rates group companies manage shortterm interest rate risk local level necessary using financial instruments interest rate forward contracts swaps options market risk changes market value certain financial assets liabilities instruments affect net income financial position group groups longterm investments held strategic purposes changes market value affect carrying value unless perma nent loss value indicated groups marketable securities held fund management purposes risk loss value reduced careful review prior investing concen tration investments continuous monitoring performance investments changes risk configuration notes consolidated financial statementscredit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focussing assessment country risk credit availability ongoing credit evaluation account monitoring procedures significant concentrations within trade receivables counterparty credit risk dueto groups large number customers wide geographical spread country risk limits exposures continuously monitored exposure financial assets liabilities credit risk controlled setting policy limiting credit exposure highquality counterparties continuously reviewing credit ratings limiting individual aggregate credit exposure accordingly liquidity risk group companies need sufficient availability cash meet obligations individual companies responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group allows make efficient use international capital markets financing pur poses group organisation overview operating subsidiaries associated companies included pages addition operating companies group holding finance companies genentech june group exercised option acquire remaining outstanding special common stock genentech inc june result genentech became wholly owned subsidiary group total consideration million us dollars million swiss francs included contribution group genentech funds required genentech purchase outstanding genentech special common stock cost genentech settling outstanding obligations employee stock option plan consid eration paid allocated assets liabilities genentech consequently total carrying value genentech increased million swiss francs part group recorded writeup inventory million swiss francs million swiss francs recognised cost sales sale inventory million swiss francs july october group sold total common stock genentech public offerings yielding total proceeds billion us dollars billion swiss francs total resulting pretax gain billion swiss francs calculated difference proceeds sales net incidental costs proportion net assets march group sold million shares genentech public offering yielding proceeds million us dollars million swiss francs resulting pretaxgain incidental costs million swiss francs roches ownership interest ingenentech december notes consolidated financial statements acquisitions divestments december group acquired global rights kytril granisetron smithkline beecham cash consideration million us dollars million swiss francs december group also sold exclusive rights coreg carvedilol united states canada smithkline beecham million us dollars million swiss francs group remain supplier carvedilol markets outside united states canada result acquisition kytril acquisition medical instruments division avl certain smaller acquisitions additional intangible assets million swiss francs recorded total cash outflow acquisitions million swiss francs inflow divestments million swiss francs notes consolidated financial statements segment information millions chf divisional information vitamins fragrances pharma fine continuing ceuticals diagnostics chemicals others operations flavours group segment revenues segment revenue divisional sales less interdivisional salesa divisional sales third parties segment results operating profit segment assets liabilities divisional assetsb segment assetsc segment assets nonsegment assetsd total assets divisional liabilitiesb segment liabilitiesc segment liabilities nonsegment liabilitiesd total liabilities segment information capital expendituree depreciation amortisation impairment longterm assets research development costs share result associated companies investments associated companies number employees transfer prices interdivisional sales set arms length basis b divisional assets consist primarily property plant equipment intangible assets receivables inventories divisional liabilities consist trade accounts payable c segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assets liabilities provisions nonsegment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments associated companies investments debt e capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions notes consolidated financial statements vitamins fragrances pharma fine continuing ceuticals diagnostics chemicals others operations flavours group segment revenues segment revenue divisional sales less interdivisional salesa divisional sales third parties segment results operating profit segment assets liabilities divisional assetsb segment assetsc segment assets nonsegment assetsd total assets divisional liabilitiesb segment liabilitiesc segment liabilities nonsegment liabilitiesd total liabilities segment information capital expendituree depreciation amortisation research development costs share result associated companies investments associated companies number employees transfer prices interdivisional sales set arms length basis b divisional assets consist primarily property plant equipment intangible assets receivables inventories divisional liabilities consist trade accounts payable c segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assets liabilities provisions nonsegment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments associated companies investments debt e capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions notes consolidated financial statementsgeographical information sales third parties destination segment assetsa capital expenditureb switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assetsc consolidated total switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assetsc consolidated total segment assets consist primarily property plant equipment intangibles receivables inventories segment liabilities included b capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions c nonsegment assets mainly include current deferred income tax assets financial assets principally cash marketable securities investments associated companies investments vitamin case following settlement agreement us department justice may regarding pricing practices vitamin market group recorded pretax expenses million swiss francs respect vitamin case cash outflows million swiss francs march us federal judge approved overall settlement agreement class action suit brought us buyers bulk vitamins several customers class action decided opt proposed settlement pursue claims group individually individual suits still process possible determine timing amount ultimate settlement claims notes consolidated financial statements october settlement agreements executed attorneys general private class counsels representing us indirect purchasers consumers states attor neys general respect governmental entities states class action settlements remain subject court approval approved roche pay million us dollars plus interest legal fees certain suits states still process possible determine outcome claims july european commission issued statement objections producers bulk vitamins including roche beginning commissions formal investi gationinto vitamin case yet possible determine ultimate outcome investigation provisions recorded respect vitamin case december less amounts utilised remain groups best current estimate total liability may arise therefore additional expenses charged net cash inflows million swiss francs following optout us buyers bulk vitamins settlement agreement group received repayment part amounts paid trust fund genentech legal settlements november groups subsidiary genentech reached settlement agreement university california regarding alleged patent infringement involving genentechs human growth hormone products furthermore genentech made payment settle investigation united states federal authorities relating past clinical sales marketing activities asso ciated human growth hormone total pretax expense recorded million swiss francs payments respect matters made givaudan spinoff millions chf june groups fragrances flavours division spun independent company name givaudan shares givaudan distributed date special dividend holders roche shares nonvoting equity securities result spinoff assets totalling billion swiss francs liabilities totalling billion swiss francs transferred givaudan results cash flows fragrances flavours division spinoff june included consolidated figures however consolidated balance sheet shown spinoff include divisions assets liabilities sales results assets liabilities net cash flows fragrances flavours division part roche group shown discontinuing operations following table notes consolidated financial statementscontinuing operations discontinuing operations group group statement income sales less interdivisional sales sales third parties operating profit financial income expense net result taxes income taxes result taxes changes accounting policies minority interests share result associated companies net income balance sheet december property plant equipment intangible assets longterm assets current assets total assets longterm debt noncurrent liabilities current liabilities total liabilities net assets statement cash flows operating activities financing activities investing activities net effect currency translation cash increase decrease cash transfer prices interdivisional sales set arms length basis notes consolidated financial statements employee benefits millions chf amounts recognised arriving operating profit follows wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans employee benefits total employees remuneration number employees yearend postemployment benefits employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic con ditions countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally usa plans usually funded payments group employees trusts independent ofthe groups finances plan unfunded liability whole obligation recorded groups balance sheet amounts recognised arriving operating profit postemployment defined benefit plans follows current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment total included employees remuneration actual return plan assets million swiss francs million swiss francs notes consolidated financial statementsthe movements net asset liability recognised balance sheet postemployment defined benefit plans follows beginning year previously reported effect implementing revised international accounting standard employee benefits restated changes group organisation givaudan spinoff total expenses included employees remuneration contributions paid benefits paid unfunded plans currency translation effects end year amounts recognised balance sheet postemployment defined benefit plans follows unfunded plans recognised asset liability actuarial present value unfunded obligations due past present employees funded plans actuarial present value funded obligations due past present employees plan assets held trusts fair value plan assets excess actuarial present value funded obligations less unrecognised actuarial gains losses unrecognised past service costs recognised asset liability funded obligations due past present employees asset liability recognised deficit recognised part liabilities postemployment benefits surplus recognised part longterm assets total net asset liability recognised amounts include nonpension postemployment benefit schemes principally medical plans actuarial present value obligations million swiss francs million swiss francs plan assets million swiss francs million swiss francs related net liability recognised million swiss francs million swiss francs actu arial gains million swiss francs million swiss francs unrecognised amounts recognised balance sheet postemployment defined benefit plans predom inantly noncurrent reported longterm assets noncurrent liabilities notes consolidated financial statements included within fair value assets funded plans groups nonvoting equity securities fair value million swiss francs million swiss francs group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used theactuarial valuations significant defined benefit plans countries stable currencies interest rates follows discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate operating income expense net millions chf royalty income operating income total operating income royalty expense restructuring expense operating expense total operating expense total operating income expense net financial income expense net millions chf gains sale marketable securities losses sale marketable securities net gain sale marketable securities interest dividend income interest expense exchange gains losses net total financial income expense net income taxes millions chf income tax expenses amounts charged income statement follows current income taxes deferred income taxes total charge income taxes groups parent company roche holding ltd several groups operating companies domiciled switzerland maximum effective rate income taxes companies domiciled basel switzerland holding companies operating companies since group operates across world subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates notes consolidated financial statementsthe groups effective tax rate differs groups expected tax rate follows groups average expected tax rate tax effect income taxable expenses deductible tax purposes benefit prior year tax losses previously recognised differences gain sales genentech shares gain sales labcorp shares impairment longterm assets vitamin case genentech legal settlements groups effective tax rate income tax assets liabilities amounts recognised balance sheet income taxes follows current income taxes current income tax assets current income tax liabilities net current income tax asset liability balance sheet deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability balance sheet amounts recognised balance sheet deferred taxes reported longterm assets noncurrent liabilities approximately respectively current deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group significant unrecognised tax losses deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year adjustment changes accounting policies issue debt instruments charged credited income statement changes group organisation givaudan spinoff currency translation effects net deferred income tax asset liability end year notes consolidated financial statements property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year adjustment change accounting policies charged credited income statement changes group organisation currency translation effects net deferred income tax asset liability end year property plant equipment millions chf buildings land machinery improve construction land ments equipment progress total total net book value beginning year currency translation effects changes group organisation including givaudan spinoff additions disposals transfers depreciation charge end year december cost accumulated depreciation net book value december capitalised cost machinery equipment finance leases amounts million swiss francs million swiss francs net book value assets amounts million swiss francs million swiss francs operating lease commitments december future minimum payments noncancellable operating leases follows within one year one five years thereafter total minimum payments total rental expense operating leases million swiss francs mil lion swiss francs group significant capital commitments purchase construction property plant equipment notes consolidated financial statements intangible assets millions chf patents licences trademarks goodwill total total net book value beginning year changes accounting policies currency translation effects changes group organisation including givaudan spinoff additions disposals amortisation charge impairment charge end year december cost accumulated depreciation end year january group recognised impairment charge million swiss francs implementing change accounting policy see note credit million swiss francs recognised based changes recoverable amounts impaired assets year investments associated companiesin millions chf group investments associated companies listed equity investments asso ciated companies accounted using equity method share net income balance sheet value laboratory corporation america holdings usa investments accounted using equity method total investments accounted using equity method laboratory corporation america holdings usa nonvoting convertible mandatorily redeemable preferred stock cost total investments associated companies laboratory corporation america holdings group noncontrolling interest laboratory corporation amer ica holdings labcorp operates clinical laboratories united states labcorp created merger roche biomedical laboratories inc national health laboratories holdings inc roche owning new company thegroup purchased nonvoting convertible preferred stock labcorp held cost portfolio investment notes consolidated financial statements june labcorp announced called redemption july outstanding convertible preferred stock redemption period group sold sufficient holding labcorps ordinary stock groups noncontrolling interest labcorp would similar level redemption date group realised pretax gain million swiss francs process october group sold shares labcorp resulting pretax gain incidental costs million swiss francs transactions resulted total cash inflow million swiss francs basilea pharmaceutica october group contributed cash million swiss francs establish newly formed swiss company basilea pharmaceutica ltd basilea group also transferred certain knowhow intellectual property antibiotics antifungals dermatology property plant equipment basilea consideration million swiss francs october group sold shares basilea group retains noncontrolling interest basilea longterm assets millions chf recognised surplus funded pension plans loans receivable prepaid employee benefits total longterm assets loans receivable comprise loans third parties term one year longterm assets consist various assets otherwise shown separately group expects toderive economic benefits one year inventories millions chf raw materials supplies work process finished goods less provision slow moving obsolete inventory total inventories inventories held net realisable value carrying value million swiss francs million swiss francs accounts receivable trade millions chf accounts receivable notes receivable less provision doubtful accounts total accounts receivable trade december accounts receivable trade include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros emu national currencies equivalent billion swiss francs billion swiss francs notes consolidated financial statements current assets millions chf accrued interest income prepaid expenses assets held sale receivables total current assets assets held sale include inventories property plant equipment longterm assets products identified divestment following year cash marketable securities millions chf equity securities bonds debentures money market instruments total marketable securities total cash total cash marketable securities equity securities consist primarily readily saleable securities bonds debentures contracted maturity amount range interest rates within one year one five years five years within one year one five years five years weighted average interest rate approximately bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december december fair value marketable securities approximately billion swiss francs approximately billion swiss francs accrued current liabilitiesin millions chf deferred income accrued payroll related items interest payable accrued liabilities total accrued current liabilities notes consolidated financial statements equity share capital december authorised calledup share capital shares nominal value chf based information supplied roche shareholders group pooled voting rights comprising hoffmann oerihoffmann families group holds shares preceding year figure include shares without pooled voting rights held outside group individual members group transactions individuals ordinary course business nonvoting equity securities genussscheine december nonvoting equity securities issued swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates inaccordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates equity instruments december group held nonvoting equity securities financial instruments acquire securities acquired pri marily meet obligations may arise respect certain groups debt instru ments groups holdings equity instruments recorded deduction equity dividends may shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribu tion holders outstanding shares nonvoting equity securities totalled million swiss francs charged retained earnings shareholders also approved special dividend respect givaudan spinoff accounting effect distribution primarily includes carrying value groups financial statements assets liabilities givaudan totalled million swiss francs included special dividend movement retained earnings earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income millions chf number shares thousands number nonvoting equity securities thousands weighted average number nonvoting equity securities held thousands total thousands basic earnings per share nonvoting equity security chf notes consolidated financial statementsdiluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security theweighted average number shares nonvoting equity securities outstanding adjusted assume conversion dilutive potential shares nonvoting equity securities net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue thousands adjustment assumed conversion convertible debt instruments dilutive thousands weighted average number shares nonvoting equity securities issue used calculate dilutive earnings per share thousands diluted earnings per share nonvoting equity security chf minority interestsin millions chf beginning year change accounting policies givaudan spinoff acquisition genentech special common stock sales genentech shares conversion option embedded lyons iv notes issued minority share group net income net tax exercise genentech stock options currency translation effects end year genentech total minority interests genentech december minority interest genentech publicly held third par ties groups transactions genentech shares described note december genentech options outstanding employee stock option plans entitled holders exercise options purchase million shares prices ranging usd usd options outstanding million exercisable date notes consolidated financial statements debtin millions chf amounts due banks financial institutions debt instruments capitalised lease obligations borrowings total debt less current portion longterm debt amounts due within one year total longterm debt shortterm debt totalling million swiss francs million swiss francs consists ofthe current portion longterm debt shown table together shortterm bank loans overdrafts shortterm debt amounting million swiss francs million swiss francs repayment terms longterm debt within one year one two years two three years three four years four five years thereafter total longterm debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value longterm debt billion swiss francs billion swiss francs calculated based upon present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows amounts due banks financial institutions interest rates amounts primarily denominated us dollars euros emu national currencies average approximately repayment dates vary years debt instruments carrying value groups debt instruments given table supplementary information groups debt instruments including redemption conversion terms ifany given pages notes consolidated financial statementseconomic interest rate held maturity swiss franc bonds bullet due principal billion swiss francs rodeo due principal billion swiss francs us dollar bonds knock due principal billion us dollars bull spread due principal billion us dollars chameleon due principal billion us dollars japanese yen bonds samurai due principal billion japanese yen swiss franc convertible bonds helveticus dividendlinked convertible bonds due principal billion swiss francs zero coupon us dollar exchangeable notes lyons ii due principal billion us dollars lyons iii due principal billion us dollars lyons iv due principal billion us dollars japanese yen exchangeable bonds sumo due principal billion japanese yen limited conversion preferred stock total debt instruments economic interest rate held maturity market rate interest date issuance similar debt instrument conversion rights discount upon issuance issue lyons iv us dollar notes exchangeable genentech shares january group issued zero coupon us dollar exchangeable notes due january principal amount million us dollars notes exchangeable shares groups subsidiary genentech time prior maturity notes exchanged genentech shares groups percentage ownership genentech would decrease net proceeds issue million us dollars million swiss francs initially allocated million swiss francs debt million swiss francs unamortised discount million swiss francs minority interest respect conversion option embedded notes million swiss francs deferred tax liability issue sumo japanese yen bonds exchangeable nonvoting equity securities april group issued japanese yen exchangeable bonds due march principal amount billion japanese yen bonds exchangeable non voting equity securities march net proceeds issue billion japanese yen million swiss francs initially allocated million swiss francs debt million swiss francs unamor tised discount million swiss francs equity respect conversion option embedded bonds million swiss francs deferred tax liability notes consolidated financial statements repayment knock us dollar bonds due date april group repaid principal amount billion us dollars us dollar bonds originally issued resulting cash outflow million swiss francs exercise helveticus swiss franc convertible bonds may helveticus dividendlinked swiss franc convertible bonds due principal amount million swiss francs exercised resulting cash outflow million swiss francs smaller amounts exercised year swiss franc convertible bonds annual payment distribution amount paid july bond chf par value place fixed rate interest annual payment distribution amount equals two timesthe ordinary andor extraordinary dividend declared one nonvoting equity security roche holding ltd business year ended december nineteen months priorto july relevant year unamortised discount included within carrying value debt instruments following unamortised discounts swiss franc bonds us dollar bonds japanese yen bonds swiss franc convertible bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount financial instrumentsin millions chf appropriate circumstances group uses financial instruments part risk management trading strategies discussed note majority derivative financial instru ments outstanding yearend consist forward contracts entered foreign affiliates purchase currencies settling intragroup liabilities notional principal values fair values carrying values derivative financial instruments held group shown table notional amounts represent amounts actually exchanged parties therefore measure groups expo sure fair value determined reference quoted market prices use established estimation techniques carrying values included consolidated balance sheet either current assets accrued liabilities notes consolidated financial statementsnotional principal carrying amount fair value value foreign currency derivatives forward exchange contracts swaps options interest rate derivatives swaps derivatives total derivative financial instruments foreign currency derivatives forward exchange contracts swaps options interest rate derivatives swaps derivatives total derivative financial instruments net unrecognised gains open contracts hedge future anticipated foreign currency sales amounted million swiss francs million swiss francs gains recognised income statement open contracts mature various dates one year balance sheet date provisionsin millions chf restructuring provisions provisions total total beginning year changes group organisation givaudan spinoff additional provisions created unused amounts reversed utilised year increase discounted amount due passage time change discounting rate currency translation effects end year current portion provisions noncurrent portions provisions total provisions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring asso ciated ongoing activities group creation provisions recorded acharge operating income except arise restructuring newly acquired companies case included acquisition accounting hence form part goodwill notes consolidated financial statements provisions consist mainly legal environmental similar matters provisions include provisions respect vitamin case see note contingent liabilities operations earnings group continue time time varying degrees tobe affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable provisions recorded respect vitamin case disclosed note provisions groups best current estimate total liability may arise various investigations outside united states america private civil suits still progress ispossible ultimate liability may different cash flow statement millions chf cash flows operating activities cash flows operating activities derived groups primary activities asdescribed divisional review calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation movements groups working capital operating cash flows also include income taxes paid activities including example thetaxes paid genentech labcorp share sales effects genentech transactions vitamin case genentech legal settlements gain sale genentech shares charge vitamin case charge genentech legal settlements genentech inventory writeup charged total adjustments noncash operating income expense expense defined benefit postemployment plans adjustments total cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity notes consolidated financial statementsproceeds issue longterm debt lyons iv zero coupon exchangeable us dollar notes due sumo exchangeable japanese yen bonds due chameleon us dollar bonds due longterm bank loans borrowings total repayment longterm debt repayment knock us dollar bonds exercise helveticus dividendlinked swiss francs convertible bonds longterm bank loans borrowings total interest dividends paid interest paid dividends paid total cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects changes group organisation well cash generated groups investments cash flows marketable securities including income capital gains losses shown net movement groups portfolio consist large number positions held longterm basis acquisitions subsidiaries associated companies products cash contribution basilea acquisition genentech special common stock acquisitions total divestments subsidiaries associated companies products proceeds sales genentech shares proceeds sales labcorp shares divestments total interest dividends received interest received dividends received total notes consolidated financial statements subsequent events annual general meeting april shareholders asked approve stock split shares nonvoting equity securities roche holding ltd ifapproved split take place changes relevant swiss company law entered force notes consolidated financial statementsreport group auditors general meeting roche holding ltd basel auditors group audited consolidated financial statements roche group pages year ended december consolidated financial statements responsibility board directors roche holding ltd responsibility express opinion consolidated financial statements based audit confirm meet swiss legal requirements con cerning professional qualification independence audit conducted accordance auditing standards promulgated swiss pro fession international standards auditing issued international federation accountants require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstate ment examined test basis evidence supporting amounts disclosures theconsolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation webelieve audit provides reasonable basis opinion opinion consolidated financial statements roche group present fairly material respects financial position december results operations cash flows year ended accordance international accounting standards comply relevant swiss law recommend consolidated financial statements submitted approved pricewaterhousecoopers ag william kirst ralph r reinertsen basel february report group auditors multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income research development balance sheet millions chf longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf cash warrants addition dividend adjusted chf cash warrants addition dividend unadjusted chf warrants held final exercise date b addition normal dividend shareholders approved share nonvoting equity security special ro centenary warrant worth chf date issue holders option cash equivalent chf c net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data multiyear overview c e f b e f warrants held final exercise date e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors multiyear overview sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others total sales geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total multiyear overviewconsolidated income statement adjusted basis reconciliation reported figures adjusted basis millions chf sales operating net third parties ebitda profit income reported financial statements discontinuing operations reclassification sales givaudan sales third parties impact fair value adjustment genentech inventories impairment longterm assets gain sale genentech shares gain sale labcorp shares income taxes change accounting policies income applicable minority interests adjusted reported financial statements discontinuing operations reclassification sales givaudan sales third parties impact fair value adjustment genentech inventories impact newrevised ias additional amortisation genentech acquisition effective january gain sale genentech shares vitamin case genentech legal settlements income taxes change accounting policies income applicable minority interests adjusted consolidated income statement adjusted basis holding finance companies boehringer mannheim far east pte ltd singapore boehringer mannheim france holding sa meylan france corange deutschland holding gmbh mannheim germany corange ltd hamilton bermuda hoffmannla roche france sas neuillysurseine france roche capital corporation panama city panama roche capital market international limited st peter port guernsey roche capital transactions limited hamilton bermuda roche china limited shanghai china roche deutschland holding gmbh grenzachwyhlen germany roche financial management inc panama city panama roche financial products limited hamilton bermuda roche finanz ag basel switzerland roche holding uk limited welwyn garden city great britain roche holdings inc wilmington delaware usa roche international finance bermuda ltd hamilton bermuda roche international finance corporation limited st peter port guernsey roche international ltd hamilton bermuda roche kapitalmarkt ag basel switzerland roche pharmholding bv mijdrecht netherlands roche treasury management europe ltd basel switzerland sapac corporation ltd montevideo uruguay syntex corporation panama city panama companies wholly owned group holding finance companiesroche securities price development share chf roche share adjusted swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security adjusted swiss market index rebased price development american depositary receipt adr usd roche adr adjusted sp index rebased roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july roche securities number shares nonvoting equity securitiesa number shares nominal value chf number nonvoting equity securities genussscheineno nominal value total data per share nonvoting equity securityc chf net income equity dividend e f stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock prices unadjusted share yearend nonvoting equity security yearend market capitalisation unadjusted millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares unadjusted priceearnings nonvoting equity securitiesgenussscheine unadjusted nonvoting equity security genussscheinconfers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value sharesand participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices stock price figures prior june adjusted effects ofthe givaudan spinoff adjustment factors used shares nonvoting equity securities factors used independent financial institutions c net income per share market capitalisation figures assume equity instruments held outstanding net income related key ratios shown special charges million swiss francs net tax incurredfollowing corange acquisition include corange respect balance sheet data e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors ticker symbols share nonvoting american equity security depositary receipt reuters roczs roczgs rohhypk bloomberg ro sw rog sw rohhy us swx swiss exchange ro rog roche securitiesoutstanding bonds summarised bond terms exchange terms warrants bull spread may warrants exercised may holder face value usd warrants received chf cash coupon issuer roche holdings inc keep well roche holding ltd attached warrants relating roche bearer shares samurai may warrants exercised june holder face value jpy billion warrants received chf cash coupon issuer roche financial management inc keep well roche holding ltd attached warrants relating roche nonvoting equity securities genussscheine lyons april notes exchangeable american depositary shares face value usd adss adjusted exchange ratio exchange coupon zero adss per usd principal amount maturity notes issuer roche holdings inc exchange ratio changed accordance inden keep well roche holding ltd ture agreement dated april effective date exchange right roche adss june group purchase note cash option holder april purchase price perusd principal amount notes usd addition notes redeemable option group whole part time april issue price plus accrued original issue discount oid helveticus july bond chf par value exchangeable one non face value chf voting equity security roche holding ltd time coupon times ordinary andor extra life bond accordance terms bonds ordinary dividend nonvoting equity additional cash payment chf made upon conver securities genussscheine sion bond chf par value issuer roche capital market international limited keep well roche holding ltd conversion right roche nonvoting equity securities roche securities outstanding bonds summarised bond terms exchange terms warrants lyons may notes exchangeable american depositary shares face value usd adss exchange ratio exchange adss per coupon zero usd principal amount maturity notes issuer roche holdings inc exchange ratio changed accordance indenture keep well roche holding ltd agreement dated may effective date june exchange right roche adss group purchase note cash optionof holder may may pur chase price per usd principal amount notes usd usd respectively addition notes willbe redeemable option group whole part atany time may issue price plus accrued original issue discount oid rodeo march warrants entitle holder march exercise date face value chf receive cash payment chf average closing coupon price nonvoting equity security period march issuer roche kapitalmarkt ag relevant price least chf keep well roche holding ltd attached warrants roche b option group nonvoting equity securities receive cash payment equal difference genussscheine relevant price chf relevant price chf chf ii buy one nonvoting equity security exercise price chf accordance terms warrants upper lower relevant price adjusted june bullet march face value chf coupon issuer roche international finance corporation limited keep well roche holding ltd chameleon july face value usd coupon issuer roche holdings inc keep well roche holding ltd roche securitiesoutstanding bonds summarised bond terms exchange terms warrants lyons january notes exchangeable genentech shares face value usd exchange ratio genentech shares per usd coupon zero principal amount maturity notes group issuer roche holdings inc theright pay cash equal market value genen keep well roche holding ltd tech shares lieu delivering genentech shares group exchange right purchase note cash option holder genentech common stock january january purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part anytime january issue price plus accrued original issue discount oid sumo march bond jpy par value exchangeable one face value jpy nonvoting equity security roche holding ltd exchange coupon ratio bonds redeemable maturity issuer roche holdings inc attheissue price plus accrued original issue discount keep well roche holding ltd oid exchange right roche nonvoting equity securities genussscheine accordance terms bonds exchange ratio adjusted june roche securities roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expense financial expense administration expense expense total expense profit year taxes taxes net profit year financial statementsbalance sheet december millions chf longterm assets participations loans group companies total longterm assets current assets accounts receivable group companies accounts receivable prepaid expenses accrued income marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies liabilities accrued liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value financial statements notes financial statements general financial statements roche holding ltd basel prepared accordance provi sions swiss company law accepted business principles valuation methods translation foreign currencies balance sheet assets liabilities disclosed net realisable values exceptions tothis rule participations shown acquisition values less appropriate writedowns marketable securities shown lower cost market value unrealised foreign currency gains balance sheet items deferred expenses income aswell foreign currency transactions translated exchange rates ruling relevant transaction dates details specific items income total income million swiss francs million swiss francs higher previous year due better operating also increased financial income taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity total equity equals total assets previous year share capital previous year share capital amounts million swiss francs consists bearer shares nominal value chf nonvoting equity securities previous year nonvoting equity securities genussscheine nominal value guarantees guarantees favour group companies total million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible pledged assets assets total book value million swiss francs previous year million swiss francs pledged security companys commitments notes financial statementsparticipations major participations listed pages important shareholders shares company issued bearer reason company notkeep register shareholders following figures based information share holders shareholder validation check annual general meeting may onother information available company previous year shares shareholders group pooled voting rights comprising dr l hoffmann ms v michalskihoffmann ms hoffmann mr hoffmann ms v oeri hoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeria previous year shares bz gruppe holding aktiengesellschaft wilen switzer landb information supplied shareholders december figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied bz gruppe holding aktiengesellschaft notes financial statements appropriation available earnings proposals general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year distribution special dividend chf gross allocating one share givaudan ltd share nonvoting equity security transfer free reserve total appropriation available earnings carried forward account appropriation available earningsreport statutory auditors general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd basel year ended december financial statements responsibility board directors responsibility express opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss pro fession require audit planned performed manner obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved ernst young ltd jrg zrcher philipp schaffter basel february report statutory auditors arctic circle tropic cancer roche tropic capricorn global market presence ct ia rcrc letic sales switzerland manufacturing argentina research development australia services financing toll manufacturing third parties austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt el salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt ia rcrc letic honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico morocco netherlands new zealand nicaragua norway pakistan panama peru philippines poland portugal puerto rico russia singapore south africa roche globale marktprsenz operating subsidiaries associated companies group holds interest switzerlandf hoffmannla roche ltd sa san jos roche servicios sa san mostofthe companies listed exceptions basel roche ltd sisseln teranol ltd jos roche costa rica sa san jos aremarked either single dot lalden roche pharma switzerland ltd czech republic roche sro prague group interest reinach roche diagnostics schweiz denmark roche hvidovre dominican double dot group interest ltd rotkreuz roche diagnostics inter republic productos rochedominicana national ltd cham roche vitamins sa santo domingo ecuador roche europe ltd birsfelden roche instrument ecuador sa quito egypt rovigypt ltd december center ltd rotkreuz roche consumer giza roche egypt ltd giza el sal health ltd kaiseraugst basilea phar vador productos roche el salvador includes changes group membership maceutica ltd basel argentinaproduc sa san salvador finland roche oy february tos roche sa qumica e industrial espoo france hoffmannlaroche olivos australia roche products pty france sas neuillysurseine produits limited dee roche vitamins roche sa neuillysurseine roche australia ptylimited french forest diagnostics sa meylan roche vita syntex australia limited north sydney mines france sa villageneuf labo roche diagnosticsaustralia pty limited ratoires roche nicholas sa gaillard castle hill austria roche austria gmbh germany roche deutschland holding vienna roche diagnostics gmbh gmbh grenzachwyhlen corange vienna bangladesh roche bangladesh deutschland holding gmbh mannheim ltd dhaka belgiumnv roche sa hoffmannla roche aktiengesellschaft brussels sa citrique belge nv tienen grenzachwyhlen roche nicholas roche vitamins nv deinzeastene deutschland gmbh eppstein dr schief roche diagnostics belgium sa brussels fer arzneimittel gmbh cologne roche bermuda syntex pharmaceuticals diagnostics gmbh mannheim galenus international limited hamilton brazil mannheim gmbh mannheim hestia produtos roche qumicos e farmacuti pharma gmbh mannheim roche vita cos sa paulo colborndawes sa mine gmbh grenzachwyhlen great paulo canadahoffmannla roche britain roche products limited welwyn limited toronto roche vitamins canada garden city roche diagnostics ltd inc cambridge ontario chile productos lewes roche vitamins uk ltd welwyn roche ltda santiago de chile china garden city roche registration limited roche china limited shanghai shang welwyn garden city greece roche hel hai roche pharmaceuticals limited las sa athens guatemala productos shanghai roche taishan shanghai roche guatemala sa guatemala city vitamin products ltd shanghai roche honduras productos roche honduras sunve shanghai vitamins ltd shang sa tegucigalpa hungary roche hun hai roche new asiatic shanghai gary ltd budapest india roche scien vitamins ltd shanghai roche tific company india private limited zhongya wuxi citric acid ltd wuxi mumbai indonesia pt roche indonesia roche diagnostics shanghai limited jakarta ireland roche products ireland shanghai roche hong kong limited limited dublin roche ireland limited hong kong roche diagnostics hong clarecastle israel roche pharmaceuti kong limited hong kong colombia cals israel ltd telaviv italy roche productos roche sa bogot costa spa milan roche diagnostics spa rica productos roche interamericana milan istituto delle vitamine spa operating subsidiaries associated companiesmilan japan nippon roche kk tokyo tary limited johannesburg south nutritec co ltd tokyo roche korearoche korea company ltd diagnostics kk tokyo roche vitamins seoul roche diagnostics korea co ltd japan kk tokyo malaysia roche seoul roche vitamins korea ltd seoul malaysia sdn bhd kuala lumpur roche spain roche farma sa madrid diagnostics malaysia sdn bhd kuala march roche vitaminas sa lumpur roche vitamins malaysia sdn madrid andreu roche sa madrid bhd kuala lumpur mexico productos syntex roche sa madrid roche diag roche sa de cv mexico city syntex nostics sl barcelona boehringer sa de cv mexico city grupo roche mannheim roche sa madrid sweden syntex de mxico sa de cv mexico roche ab stockholm roche diagnos city lakeside de mxico sa de cv tics scandinavia ab bromma taiwan mexico city moroccoproduits roche roche products ltd taipei roche diag sa casablanca netherlands roche nostics ltd taipei roche vitamins pharmholding bv mijdrecht roche taiwan limited taipei thailand roche nederland bv mijdrecht roche diag thailand limited bangkok rovithai nostics nederland bv almere new limited bangkok roche diagnostics zealand roche products new zealand thailand limited bangkok turkey limited auckland roche vitamins new roche mstahzarlar sanayi anonim zealand limited auckland roche sirketi istanbul roche diagnostik sis diagnostics new zealand pty ltd auck temleri ticaret istanbul uruguay land nicaragua productos roche roche international ltd montevideo nicaragua sa managua norway sapac corporation ltd montevideo roche norge oslo pakistan roche usa roche holdings inc wilmington pakistan ltd karachi panama produc delaware hoffmannlaroche inc tos roche interamericana sa panama nutley new jersey rochelaboratories city productos roche panam sa inc nutley new jersey roche vitamins panama city peru productos roche inc parsippany new jersey roche qumica farmacutica sa lima philip molecular systems inc pleasanton pines roche philippines inc makati california american roche interna roche vitamins philippines inc manila tional inc little falls new jersey roche poland roche polska sp z oo warsaw carolina inc florence south carolina roche diagnostics polska sp z oo genentech inc south san francisco warsaw roche witaminy polska sp california syntex usa llc palo zoo mszczonw portugal roche far alto california roche colorado corpo macutica qumica lda amadora roche ration boulder colorado bayer sistemas de diagnsticos sociedade roche llc morristown new jersey unipessoal lda lindaavelha puerto laboratory corporation america rico syntex puerto rico inc humacao holdings burlington north carolina russia roche moscow ltd moscow roche diagnostics corporation indiana singapore roche singapore pte ltd polis indiana venezuela productos singapore roche diagnostics asia roche sa caracas pacific pte ltd singapore roche vita mins asia pacific pte ltd singapore south africa roche products proprie operating subsidiaries associated companies published f hoffmannla roche ltd basel switzerland tel fax media office corporate communications basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publications email baselwebmasterrochecom trademarks mentioned enjoy legal protection roche annual report published german next annual general meeting original language english april roche annual report issued f hoffmannla roche ltd basel corporate communications design wirz identity ag zurich typesetting staufferfebel ag basel lithos photolitho sturm ag muttenzbasel printers birkhusergbc ag graphische unternehmen reinachbasel binding buchbinderei grollimund ag reinachbasel cover background picture shows computerassisted molecular modelling active ingredient herceptin drug treatment breast cancervitamins fine chemicals diagnostics sales division pharmaceuticals latin america others asia sales region europe north america vitamins fine chemicals others diagnostics employees division pharmaceuticals latin america others asia employees region north america europe adjusted basis